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CHAPTER I 
ABSTRACT 
Hepatitis C Virus (HCV) infects 170 million individuals worldwide. Although 
several newly FDA approved drugs targeting the HCV serine protease and polymerase 
have shown promising results, there is a need for better drugs that are effective in treating 
all HCV genotypes and subtypes to be used in an interferon-free regimen. On the other 
hand, malaria is another public health burden that causes 219 million clinical episodes, 
and 660,000 deaths per year. In addition, 3.3 billion people live in areas at risk of malaria 
transmission in 106 countries. It is alarming that 86% of deaths caused by malaria globally 
were in children. Several challenges are faced when treating malaria, such as resistance 
against drugs that are used in treatment. This necessitates the development of new classes 
of drugs to overcome resistance. 
CD81 is a target protein that plays an essential role in the internalization of HCV 
into hepatocytes. Thus it was also targeted to identify sets of small molecule ligands 
predicted to bind to several sites that were identified to be involved in HCV infection. 
Thirty-six ligands predicted by AutoDock to bind to these sites were tested experimentally 
to determine if they bound to CD81-LEL. Binding assays conducted using surface 
Plasmon resonance revealed that 23 out of 36 of the ligands bound in vitro to the 
recombinant CD81-LEL protein.  
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In an effort to create new drugs that block hepatitis C virus entry into hepatocytes, 
we have designed and synthesized a small molecule that targets the HCV E2 glycoprotein 
binding site on CD81. A selective high affinity ligand (SHAL) (11) was created by linking 
together two small molecules that were predicted by docking and were shown by 
experimental methods to bind to the same site on CD81 where E2 binds. SH7153 was 
found to bind to recombinant CD81-LEL with a Kd of 21 µM but wasn’t found to inhibit 
HCV infection when tested using Raji cells (antibody neutralizing assays) and HCV 
infection inhibition assays. This led to the conclusion that the linkers’ lengths should be 
optimized so as to have a SHAL that fits properly in the desired binding sites.  
The HCV glycoprotein E2 has also been shown to play an essential role in 
hepatocyte invasion by binding to CD81 and other cell surface receptors. Recently, 2 
research groups were able to resolve the core structure of HCV E2 which will largely help 
providing structural information that can now be used to target the E2 protein and develop 
drugs that disrupt the early stages of HCV infection by blocking E2’s interaction with 
different host factors. By targeting conserved E2 residues among different genotypes and 
subtypes in the CD81 binding site on HCV E2, one might also be able to develop drugs 
that block HCV infection in a genotype-independent manner. Using the E2c structure as 
a template, we have used homology modeling methods to develop a structural model of 
the E2 protein core (residues 421-645) that includes the three amino acid segments that 
are not present in the E2c structure. Blind docking to this model was then performed using 
a library of ~4000 small molecules and a set of 40 ligands predicted to bind near conserved 
amino acid residues involved in the HCV E2: CD81 interaction were selected for 
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experimental testing. Surface Plasmon resonance was used to screen the ligands for 
binding to recombinant E2 protein and the best binders were subsequently tested to 
identify compounds that inhibit the infection of hepatocytes by HCV. One compound, 
281816, inhibited infection by HCV genotypes 1a, 1b, 2a, 2b, 4a and 6a with IC50’s 
ranging from 2.2 uM to 4.6 uM. Such inhibitors may represent a new paradigm for HCV 
treatment. In an attempt to make 281816 more promising, a SHAL prototype was designed 
using an analogue of 281816 (SH2216). It would be tempting to test the SHAL inhibitory 
effect and compare it to the 281816’s inhibitory effect.  
To date, human CD81 (hCD81) is the only human surface protein known to play 
a role in the process by which sporozoites of several Plasmodium species infect human 
hepatocytes. Blocking a human receptor that is exploited for the entry process of 
pathogens has been proven to be a good strategy for fighting drug-resistant mutants. 
Hence, we targeted the 21 amino acid stretch on CD81 large extracellular loop that was 
found to be involved in Plasmosium yoleii invasion via virtual screening runs, preliminary 
binding assays and sporozoite invasion assays. This led to the identification of 4 drug 
leads that range between moderate and strong inhibitors of infection by Plasmodium yoleii 
and Plamodium falciparum. Additionally one ligand was found to potentiate the invasion 
of Plasmodium yoleii.  
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CHAPTER II 
 LITERATURE REVIEW 
Parts of the literature review are adapted from the M.Sc. thesis – By: Al Olabi, 
Reem Rafik (2010-07-19) - The American University in Cairo “In silico design of 
selective high affinity ligands against HCV using novel computational biology 
tools”  
A) Hepatitis C Virus 
1. History 
In early 1970s researchers discovered that there were more than the two known 
serotypes of hepatitis, hepatitis A and B. A third type was discovered and it was called 
none A non B (NANB) hepatitis. This discovery was a result of extensive work, which 
began by monitoring the participants in the study analyzing an abnormal pattern of 
aminotransferases bi-monthly for 6 to 12 months. This was followed by transfusion 
studies that were an eye opener on acute hepatitis. It was believed that the transfusion 
associated hepatitis would be hepatitis B but it wasn’t. This was proven when the samples 
were found to be non-reactive to hepatitis B tests. The stored sera from the transfusion 
studies were then used to inoculate chimpanzees, which later on developed biochemical 
abnormalities (e.g. elevated aminotransferases) indicating that NANB type was a 
transmissible agent. After 15 years of research, hepatitis C was identified by Houghton et 
al. (1). Specific serological tests were developed and a comparison between NANB and 
HCV confirmed that they are the same (2).  
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2. HCV genomic diversity  
There are six major genotypes of HCV worldwide with RNA sequences that differ 
by >30 %. These genotypes are further classified into subtypes, isolates and quasispecies 
(3). The continuous mutation of HCV is due to lack of efficient proof reading by the RNA 
dependent RNA polymerase in addition to the lack of the 5’ to 3’ exonuclease activity 
which leads to accumulation of mutations and viral escape (4). The host immune’s 
response is one of the major factors that affect the persistence of HCV infection leading 
either to viral clearance or to chronic infection. It is believed that there are positive and 
negative selection processes in which the beneficial mutations are selected and favored 
over deleterious ones (5). The HCV genotype is one of the most important predictive viral 
factors for the response to therapy. Other factors affecting response to therapy include sex 
and age of the patient, the initial viral load and the presence or absence of liver fibrosis 
(4). 
3. HCV Life Cycle 
3.1. Proposed model of HCV entry into hepatocytes 
HCV entry into the host cells involves several host receptors such as CD81 (6, 
7, 8), the tight junction protein Claudin-1 (CLDN-1) (6, 9), scavenger receptor class 
BI (6, 8, 10). LDL-R (6, 8), mannose binding lectins DC-SIGN and L-SIGN (6), 
heparan sulfate proteoglycans (11, 6) and the asialoglycoprotein receptor (6). LDL-R 
and heparan sulfate play the initial role by mediating the attachment of HCV to CD81 
and SRBI which upon interacting will trigger HCV movement and internalization via 
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CLDN-1 and occludin (11). Figure 1 shows the proposed HCV entry mechanism (11, 
12).  
It was proposed that HCV particles become associated with low density 
lipoproteins (LDL) and very low density lipoproteins (VLDL) leading to the 
conclusion that LDL receptors are involved in the entry. Glycosaminoglycans (GAGs) 
and LDL-R function as primary receptors that mediate the attachment of HCV to 
CD81 and SR-BI (11, 12). CD81 and SR-BI in turn triggers HCV movement towards 
the tight junction proteins; claudin-1 (CLDN1) and occluding (OCLDN) which act as 
co-receptors (11, 12). The tight junction proteins act at a late stage of entry which is 
followed by the internalization of HCV through Clathrin-mediated endocytosis. It was 
suggested that HCV then moves inside the host cell in a low pH endosome where the 
acidification of the endosome helps mediate an HCV glycoprotein: endosomal 
membrane fusion (12, 13). It was found that the envelope proteins of other flaviviruses 
and alphaviruses (such as Semliki Forest virus and Dengue virus) possess an internal 
fusion peptide (class II fusion protein) that rearranges and trimerizes when exposed to 
low pH. This led to an assumption that HCV could involve class II fusion proteins in 
its internalization process (12).  
3.2. Polyprotein Synthesis 
This step begins with the decapsidation of the HCV nucelocapsid releasing the 
free positive stranded HCV genomic RNA which in turn acts as a mRNA with the newly 
synthesized RNA. This is followed by the translation of the HCV genome which is IRES-
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dependent to produce the structural and nonstructural proteins needed for the completion 
of the life cycle, assembly and infecting other cells (14, 15). A cap-independent internal 
initiation of HCV polyprotein translation is mediated by IRES via recruiting both cellular 
proteins, including eukaryotic initiation factors (eIF) 2 and 3 and viral proteins (16, 17, 
18). It was found that the core protein and nonstructural proteins NS4A and NS5B alters 
the IRES translational efficiency (19, 20).  
3.3. HCV Replication 
 Rearrangements of intracellular membranes are induced by the Infection with the 
HCV positive-strand RNA virus and HCV NS4B protein was found to induce the 
formation of the membranous web necessary for replication (21, 22). The membranous 
web is derived from ER membranes (23). The membranous web consists of small vesicles 
embedded in a membranous matrix, forming a membrane-associated multiprotein 
complex that contains all of the nonstructural HCV proteins (21). HCV replication is 
catalyzed by the NS5B RNA-dependent RNA polymerase (RdRp). The positive-strand 
genome RNA serves as a template for the synthesis of a negative-strand intermediate of 
replication during the first step. In the second step, negative-strand RNA serves as a 
template to produce numerous strands of positive polarity that will subsequently be used 
for polyprotein translation, synthesis of new intermediates of replication or packaging into 
new virus particles (23).  
3.4. Virus Assembly and Release 
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Initiation of virion assembly requires release of replicated genomes from the 
endoplasmic reticulum to allow their contact with core protein, which forms the HCV 
capsid. Assembly is thought to initiate in the cytosol before further maturation, and release 
occurs by transfer of nascent particles across the ER membrane to enable access to the 
secretory pathways in hepatocytes [24].  
To sum up the assembly and release of HCV particles, it is divided into 3 stages 
that are interconnected: (i) an initial phase of assembly at LDs, (ii) the contribution made 
by viral factors that probably takes place after assembly has begun, (iii) and events on the 
lumenal side of the ER membrane where there is engagement with the VLDL assembly 
pathway to facilitate virion maturation and release (figure 2). 
4. HCV Epidemiology  
Hepatitis C virus infects around 200 million of the world population (figure 3). In 
the developed countries, the chronic HCV infection accounts for 80% of the patients, and 
acute HCV for 20%. 40% of the infected patients’ progress to end stage cirrhosis, 60% to 
hepatocellular carcinoma and 30% require liver transplantation (25). Chronic hepatitis C 
prevalence ranges from 0.1% to 14.5% in different countries (26) and Egypt has the 
highest HCV prevalence worldwide (15%).  
5. HCV genome and proteins 
HCV is a positive strand-RNA virus possessing a genome of approximately 9.5 
kilobases which encodes a large polyprotein containing 3010 amino acids (figure 4) (14). 
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The processing and cleavage of the polyprotein is performed using the machinery of the 
host and enzymes produced by the virus. Ten structural and non-structural proteins are 
produced upon cleavage of the polyprotein. Either pathway involves peptidase cleavage 
signals (27). There are two untranslated regions (UTRs) one at the 5’ end and one at the 
3’ end of the RNA (figure 4) (28, 29).  
The structural proteins are the envelope glycoproteins denoted E1 and E2 and the 
core protein.  There are two other proteins of unknown significance known as “p7” and 
“F” proteins (28, 30). As for the non-structural proteins; they are denoted NS2, NS3, 
NS4A, NS4B, NS5A, and NS5B (27, 30). The structural proteins are released by the host 
machinery in the endoplasmic reticulum, whereas the non-structural proteins are released 
following cleavage by NS2-3 and NS3/4A protease. The C terminus of the capsid protein 
undergoes further processing triggered by a signal peptide peptidase (29).  
Table 1 provides a brief description of the HCV proteins and their functions. Since 
the main HCV targets in this phase are HCV E2 glycoproteins, and HCV NS3/4A 
complex, the next few paragraphs will provide more details on their nature and function 
(29).  
6. HCV Envelope glycoproteins   
E1 and E2 glycoproteins are type I transmembrane proteins that possess a C-
terminal transmembrane domain and an N-terminal ectodomain that is N-linked to 
glycans. The glycans were found to play a role in virus entry and glycoprotein folding 
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(27). ). Since HCV envelope glycoproteins are highly glycosylated, carbohydrate binding 
agents (CBA) such as cyanovirin-N might prove to be promising in blocking HCV entry 
into the cells (31). Both proteins are cleaved from the polyprotein by host signal peptidase 
cleavage (18). E1 and E2 form a natural non-covalent heterodimer that is retained in the 
endoplasmic reticulum (ER) (27, 32). Their retention in ER contributes to HCV infection 
conversion into the chronic form because it cannot be detected by the host immune system 
and also proves that the virus is released from the host cells by budding and exocytosis 
(27).  
Several host receptors were found to be involved in HCV entry by either mediating 
viral attachment such as LDL-R and heparan Sulfate (23) or by interacting with HCV E2 
glycoprotein such as CD81 and scavenger receptor BI (SR-BI) (24-26). These interactions 
trigger HCV movement to the tight junctions and its uptake by Claudin-1 and its uptake 
via Claudin-1 and occludin (1). Two hypervariable regions (HVR) have been identified 
in the HCV E2 glycoprotein sequence. HVR-1 is formed from the first 27 amino acids of 
the E2 N-terminus (ectodomain), and it largely contributes to the escape of the virus from 
the host immune response. HVR-1 has also been shown to modulate HCV entry.  As for 
HVR-2, it has been described as an HCV entry modulator (27, 32). Viral glycoproteins 
such as HCV E2 are considered to be a promising target to generate drug against because 
it plays an important role in host cell interaction and thus if blocked will dissect the HCV 
life cycle in its earliest phase. HCV envelope glycoproteins are believed to belong to class 
II fusion proteins according to the model created by Yagnik et al. (33). Recently, 2 new 
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studies were done that showed that HCV E2 doesn’t belong to the class II fusion proteins 
as will be shown in the next section (38,39). 
7. E2 Homology models and resolved peptides and crystal structures 
There is no crystal structure available for HCV E2 glycoprotein, nor are there 
reliable homology models except for that developed by Yagnik et al. (33). It is strongly 
believed that developing a reliable model of HCV E2 will be considered a break through 
because it will open another path for new category of anti-HCV drugs based on fragment 
based drug design and selective high affinity ligands approach.  
Yagnik et al. (33) applied several fold recognition methods (such as TOPITS and 
THREADER2) to develop an HCV E2 model using the envelope protein E of Tick Borne 
Encephalitis virus as a template. In addition they constructed two truncated E2 proteins 
by PCR. These two proteins (N2 and H strains) were used in heparin and CD81 binding 
studies. The aim of those binding studies was to map the results obtained from 
experimental studies they performed onto their E2 model with the goal of identifying 
important residues involved in 'E2:CD81 interaction and a heparin binding domain. The 
results obtained in this study were also used to propose a rough model for the quaternary 
structure of the envelope glycoproteins E1 and E2 complex (34). 
 The C-terminal ends of the E1 and E2 glycoproteins play important roles in E1-
E2 heterodimerization and retention in (ER). Charloteaux et al. (35) examined the C-
terminal sequences of E1 and E2 in 25 HCV strains and used these sequences to generate 
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several 3-D models. They found out that both domains of E1 and E2 should have a 
configuration of one amphipathic α helix followed by a pair of transmembrane strands. 
After generating 3-D models and minimizing the energy, the molecular hydrophobicity 
potentials (MHP) calculation and the IMPALA procedure (a Monte Carlo minimization 
of energy based simulation) were used to evaluate the C-terminal domains’ interaction 
with the membranes. They concluded that the created 3-D models were consistent with 
the experimental studies in that both C-terminal domains are involved in ER retention and 
in E1-E2 heterodimerization (35).  
Yu et al. (36) created a structural model of the HCV E2 protein using the Yagnik 
et al. (33) sequence alignment. The template used was the crystal structure of the tick-
borne encephalitis virus (TBEV) soluble E protein. The ectodomain of HCV E2 in this 
model was similar to that of domains I and II of TBEV E protein and HCV E1 glycoprotein 
was similar to domain II of TBEV E protein. They proposed that E1 and E2 glycoproteins 
form a tetramer that forms the basic building block of the outer shell of HCV where as in 
case of flavivirus (TBEV) the outer shell is formed of E-protein dimers (36).  
Spiga et al. (37) reported a 3-D structure for the HCV E2 homodimer that was 
developed based on a secondary structure prediction using PsiPred. This was followed by 
fold recognition using GenThreader v.2.1. software. They used both the TBEV E-protein 
as a template and the alignment of the consensus sequence of six HCV E2 genotypes (1a, 
1b, 2a, 2c, 3a, 4c) in building the E2 model using DeepView v.3.7 software. The model’s 
sequence identity with the template was 14% and the structure exhibited little secondary 
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structure (mainly B-sheets). In addition, molecular docking simulations were conducted 
to predict the HCV E2 dimeric assembly. The aim of the study conducted by Spiga et al. 
was to find surface exposed protein sequences that could be immunoreactive in the HCV 
E2 glycoprotein (E2 mimotopes) and also common in most genotypes. Nine fragments 
were selected in the developed model, synthesized on nitrocellulose membranes and tested 
through binding assays using phosphate conjugated anti-HCV human antibodies. This 
approach was considered important because it might be used to develop diagnostic kits 
(37).  
Recently, Kong et al. (38) and Khan et al. (39) have been able to resolve the crystal 
structure of the core of the HCV E2 glycoprotein. Kong et al. (38) obtained the structure 
of amino acid residues 384-746 (E2c) by designing and expressing 41 soluble HCV E2 
constructs and selecting 15 to screen against E2-specific Fab fragments in crystallization 
trials. Using a combination of x-ray crystallography and negative stain-electron 
microscopy, Kong et al. (38) discovered that the structures they obtained for E2 were 
globular and very different from the predicted models of E2 that were developed using 
class II fusion protein templates containing three β-sheet domains (figure 5).  
Additionally, they were able to identify key CD81-binding residues through 
mutational studies. The CD81 binding sites were determined to be in the AR3C epitope, 
along one side of the B-sandwich (an isolated region of the CD81-binding loop) and a 
front layer consisting of loops, short helices and β-sheets (38). AR3C was also found to 
cross-neutralize HCV genotypes by blocking CD81 binding to HCV E2 (38). On the other 
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hand, the resolved structure of Khan et al. (39) were reported to be crystallized in complex 
with a FAB fragment of the mouse monoclonal antibody 2A12, and it was found to be 
highly similar to the previously reported structure (figure 6). 
8. Significance of CD81 in HCV Infection  
Several research groups have found that the CD81- large extracellular loop 
(CD81-LEL) is the domain involved in HCV entry via interaction with HCV E2 
glycoprotein (40,41). Higginbottom et al. (42) identified 4 amino acid residues that are of 
large significance in the E2-CD81 interaction using mutational studies. They found that 
the D196E mutation reduced the binding to E2. In addition mutations F186L and E188K 
inhibited binding of CD81 to E2 whereas T163A enhanced their fusion (42). Drummer et 
al. (43) identified an E2 binding site in CD81-LEL to occupy around 806 A°2. The most 
important contact residues they found within this site were Ile182, Phe186, Asn184, and 
Leu162 (43). The identification of these residues provides new targets for the design of 
selective high affinity ligands that could inhibit E2-CD81 interaction. Zhang et al. (44) 
also discovered a novel function for CD81 in HCV life cycle. They found that CD81 is 
important for efficient HCV genome replication.  
This same group also discovered that the E2-CD81 interaction had several 
immuno-modulatory implications, among which include inducing in vitro a co-
stimulatory signal in naive and antigen-experienced T cells leading to production of pro-
inflammatory cytokine gamma interferon. Thus the CD81-E2 interaction might play a role 
in T-cell-mediated liver inflammation and lead to liver damage. In addition, the interaction 
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of these two proteins down regulates T cell receptors and suppresses the activity of natural 
killer (NK) cells (43). Brazzoli et al. found out that CD81 is a central regulator for several 
events within the HCV life cycle. CD81 was found to activate Rac, Rho, and Cdc42 (Rho 
GTPase family) mediating the contact between HCV E2/CD81 complex with CLDN-1 
and occludin tight junction proteins to internalize HCV into the cell. Thus inhibiting 
CD81-HCV E2 interaction will block these events as stated and will massively reduce the 
infectivity of HCV (figure 7) (45,46). Figure 7 illustrates the role of CD81 in disrupting 
the host immune response against HCV. On the initiation of HCV infection, the CD81: 
HCV E2 interaction on the surface of different immune cells leads to activation, 
aggregation, increased survival of B cells and triggers VH gene hypermutation. This is 
thought to cause the HCV-induced mixed cryobulinemia and non-Hodgkin’s lymphoma 
(45). Additionally, this interaction leads to the activation of the protein tyrosine kinase 
Lck which might be responsible for the presence of auto-reactive T cells in patients 
infected with chronic HCV (45,46). On the other hand, the HCV E2: CD81 interaction 
might also lead to the production of a ligand for the CCR5 receptor (RANTES) which 
when ligates to CCR5 at the surface of pDCs ends in priming T cells and decreasing the 
secretion of IFN-α and impaired maturation, proliferation and survival of these cells 
(45,46). On the whole, impairment of pDCs and NK cell functions might explain the 
establishment of chronic HCV infection (45). 
To conclude the significance of CD81 in HCV infection, it is considered a key 
player in regulating HCV life cycle where it controls the initiation of the infection. CD81 
is also involved in triggering the host response due to HCV infection, in addition to the 
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replication and dissemination of HCV. The significant functions that CD81 plays in HCV 
infection are reviewed in (46). 
9. HCV treatment 
Sustained virologic response (SVR) is defined as “having no detectable viral RNA 
after completion of antiviral therapy.” (47). The main aim of any anti-HCV treatment is 
to achieve SVR since it is accompanied with better clinical outcomes, lower rates of HCV-
related morbidity and mortality, and stabilization of liver histology (47,48). The SVR was 
assessed after the end of therapy by 6 months. Recently, the assessment is also done after 
12 weeks of end of therapy so as to stop the treatment after 12 weeks if the SVR is 
achieved (48).  
The HCV Standard of Care (SOC) for many years was a combination of 
peginterferon (PEG-IFN) and ribavirin (RBV) owing to it being the only FDA approved 
combination therapy for HCV (49). This treatment was shown to have many side effects 
that could lead to the non-adherence to the assigned regimen in addition to having 
different rates of response to it depending on the HCV genotype and subtype.  
Great efforts are being carried out to produce new drugs with higher efficacy, and 
better patient compliance being of less side effects, frequency and route of administration. 
The life cycle of HCV has several steps of interest that could be targeted and yield 
promising classes of drugs. Among the classes that are being developed are NS3 protease 
inhibitors, NS5B polymerase inhibitors, ribavirin analogs and cyclophilin inhibitors 
(figure 8) (50). On the other hand, different research groups were working on resolving 
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the structure of HCV E2 so as to help in creating anti-HCV vaccines and drugs by 
targeting HCV E2. Additionally, there are several efforts done to target the entry stage in 
the HCV life cycle through targeting the host factors involved in HCV entry into 
hepatocytes that were discussed in the HCV life cycle section. 
9.1. Drugs Targeting HCV (Directly Acting Antivirals “DAAs”)  
9.1.1. Protease Inhibitors  
HCV serine protease has been extensively studied at the biochemical level and its 
structure is known (51,52). The NS3 serine protease is located in the N-terminal region of 
NS3 and is associated with the NS4A cofactor. Being one of the characterized HCV 
proteins, it became a potential anti-HCV drug target. The NS3/4A protease inhibitors can 
be divided into two chemical classes: macrocyclic inhibitors and linear tetrapeptide a-
ketoamid derivatives.  
Serine protease inhibitors range from being of low to high genetic barrier where 
genetic barrier is the number of aminoacid mutations needed to confer resistance to the 
drug used in treatment. The protease inhibitors of low genetic are more prone to HCV 
resistance needing only single mutation in the HCV particle whereas those of high barrier 
are less prone to resistant HCV strains since they need more than one mutation (53). 
Simeprevir is the newly FDA approved oral protease inhibitor (50). Its efficacy has been 
established in combination with peginterferon alfa and ribavirin in patients with HCV 
genotype 1 infection with compensated liver disease (including cirrhosis). In Table 2, the 
current protease inhibitors that are in different clinical phases, the manufacturing 
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company, the chemical structure being linear or macrocyclic, the genetic barrier, the 
required dose per day, their IC50 values, and the genotypes they are active towards are 
enumerated (53).  
9.1.2. Polymerase Inhibitors  
Polymerase inhibitors bind to NS5B RNA-dependent RNA polymerase. NS5B 
RNA interfering with the viral replication. They are categorized into 2 different types: 
nucleoside inhibitors (NI) and non-nucleoside inhibitors (NNI). NI mimic the natural 
substrates of the polymerase thus incorporated into the RNA chain causing direct 
chain termination (54, 55). They require conversion to an active triphosphate form. 
On the other hand, NNI bind to several discrete sites outside of the HCV polymerase 
active center, resulting in conformational changes in the HCV polymerase before the 
elongation complex is formed (54,55). Sofosbuvir is the most significant newly FDA 
approved oral HCV drug and polymerase inhibitor. Sofosbuvir is used in combination 
with ribavirin or ribavirin plus interferon to treat HCV genotypes 1,2,3 and 4.  
9.1.3. NS5A Inhibitors 
The NS5A is a membrane-associated phosphoprotein in the HCV genome, 
which is present in phosphorylated (p56) and hyper-phosphorylated (p58) forms (55–
57). It is involved in HCV virion production and has significant roles at various stages 
of HCV life cycle. NS5A has been shown to play a role in conferring resistance to 
interferon via interaction with a number of host proteins in vivo (55, 56). Daclastavir, 
an NS5A inhibitor, was found to be active at picomolar concentrations in HCV 
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replicons expressing a broad range of HCV genotypes (55–57). Accordingly, it might 
be another holy grail in the field of HCV treatment.  
9.1.4. Targeting HCV E2 to develop anti-HCV drugs and vaccines 
Several approaches are being used to develop anti-HCV drugs and vaccines that 
target the HCV E2 glycoprotein. Developing monoclonal and polyclonal antibodies is one 
of the approaches used. XTL Biopharmaceuticals reported that a combination of the 
monoclonal antibodies AB68 and AB65 (AB6865) was more effective than each one 
alone (58). Both monoclonal antibodies were obtained by immortalizing peripheral blood 
mononuclear cells obtained from the blood of HCV infected patients. It was observed that 
AB6865 combination can identify different conformational epitopes on E2 and immune-
precipitate different strains of HCV particles. The viral clearance takes place upon 
formation of immune complexes by endocytosis since that AB6865 induces phagocytosis 
of the immune complexes by neutrophils (58-61).  
Bavituximab® is another monoclonal antibody developed by Peregrine 
pharmaceuticals that acts against a unique target, phosphatidyl serine. Phosphatidylserine 
is a lipid molecule normally found in the interior of cellular membranes and becomes 
exposed on the cell surface of cell membranes of viruses and host infected cells during 
replication. It has been reported that the presence of the phosphatidyl serine on the surface 
of the membranes of viruses creates a masking effect and thus helps the virus to evade the 
host immune response. This monoclonal antibody can be used against several viruses such 
as HIV, CMV, influenza and HCV. When comparing Bavituximab with other monoclonal 
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antibodies, it was found to be more advantageous because it has high specificity towards 
cells infected with viruses only. In addition it targets a molecule in the host and thus won’t 
be affected by any viral mutations (62, 63).  
Human hepatitis C immune globulin or Civacir is a polyclonal antibody obtained 
from human plasma enriched with HCV polyclonal antibodies collected from screened 
donors. It is used to prevent the re-infection of HCV infected patients who had a liver 
transplant (64).  
Another approach is to develop a vaccine that triggers passive immunity against 
HCV. It was found that immunoglobulin G obtained from HCV infected patients could be 
a good candidate for developing such a vaccine. Vanwolleghem et al. (64) injected 8 
chimeric mice with immunoglobulin G obtained from HCV infected patients, which were 
then challenged with 100% infectious dose of the acute phase HCV. Five out of eight mice 
developed immunity against HCV. Law et al. (65) were able to isolate polyclonal 
antibodies that bind specifically to HCV E2 and neutralize several HCV strains. Full 
length immunoglobulins G were obtained from 3 antibody-antigen binding fragments that 
bound to 3 antigenic regions on E2. Monoclonal antibodies were obtained from these 
immunoglobulins and were injected intraperitoneally in mice with high levels of human 
liver chimerism. These mice were then challenged by HCV infected human serum, but 
the monoclonals didn’t show the desired effect (65).  
A third approach involves carbohydrate binding agents (CBA) against HCV E2. 
Since HCV envelope glycoproteins are highly glycosylated, carbohydrate binding agents 
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(CBA) such as cyanovirin-N might prove to be promising in blocking HCV entry into the 
cells (66). Several host receptors were found to be involved in HCV entry by either 
mediating viral attachment (such as LDL-R and heparan sulfate) (67) or by interacting 
with HCV E2 glycoprotein (such as CD81 and scavenger receptor BI (SR-BI)) (68-70). 
Based on these findings new approaches were opted such as developing small molecules 
that mimic the D-helix of CD81 and is known to interact with HCV E2 (71).  
9.2. Drugs Targeting Host factors at the entry level  
HCV entry inhibitors target the first steps of HCV life cycle. Several studies 
showed that they efficiently inhibit cell to cell transmission which is one of the significant 
contributors to the spread of the virus throughout the liver. This makes this class of drugs 
suitable for preventing liver graft infection which increases the rate of success of liver 
transplantation. On the other hand, there are other host factors that are involved in the 
immunomodulatory mechanisms that is controlled by HCV. They could be promising 
targets as well. What makes targeting host factors of potential interest is the high genetic 
barrier to resistance of some DAAs (72). 
9.3. Targeting CD81-LEL to develop anti-HCV drugs 
Several research groups have found that the CD81- large extracellular loop 
(CD81-LEL) plays a key role in HCV entry into cells by binding to the HCV E2 
glycoprotein (10, 42, 73). Higginbottom et al. (42) and Drummer et al. (43) used 
mutational studies to identify residues that contribute to the E2-CD81-LEL interaction 
42). This information is important because it can be used to direct the design of a series 
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of selective high affinity ligand-based inhibitors that block the E2-CD81-LEL interaction. 
(42,43). Zhang et al. (44) discovered a separate, additional function for CD81 in the HCV 
life cycle. These studies showed that CD81-LEL is important for efficient HCV genome 
replication where the level of CD81 expression was found to modulate the HCV RNA 
replication.  
In addition, E2-CD81-LEL interaction induces several immuno-modulatory 
effects, including co-stimulatory signal in naive and antigen-experienced T cells that leads 
to the production of pro-inflammatory cytokine gamma interferon. Thus the CD81-E2-
LEL interaction may play a role in T-cell-mediated liver inflammation and contribute to 
liver damage. In addition, the interaction of these two proteins down regulates T cell 
receptors and suppresses the activity of natural killer (NK) cells (43). Meuleman et al. 
(74) showed that using anti-CD81 as a prophylactic treatment completely protected 
human liver-uPA-SCID infection with different genotypes of HCV (74).  
9.4. Other host factors Entry Inhibitors 
HCV entry is considered one of the potential targets for creating an anti-HCV drug. 
Several host factors are involved in the entry of HCV into hepatocytes. Intervening with 
such mechanisms and blocking it might help in preventing both invasion of the virus, and 
cell to cell transmission. Table 3 enumerates several classes of entry inhibitors that target 
different host factors (72).  
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11. Tables 
Table 1. HCV proteins. This table shows the 10 HCV proteins, their molecular mass and 
their function.  
Protein Molecular mass 
KDa  
Function 
Core 21 RNA binding, nucleocapsid 
E1 31-35 Envelope glycoprotein, associate with E2 
E2 70 Envelope glycoprotein, associate with E2, receptor 
binding 
P7 7 Ion channel 
NS2 21 Component of NS2-3 proteinase 
NS3 69 N-terminal proteinase domain/ C-terminal  
NTPase/Helicase domain 
NS4A 6 NS3/4A proteinase co-factor 
NS4B 27 Induces membrane alterations 
NS5A 56-58 Phosphoprotein 
NS5B 68 RNA dependent RNA polymerase 
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Table 2. HCV protease inhibitors in different clinical phases (50).  
Protease 
Inhibitors 
Company Clinical 
Phase 
Chemical 
Structure 
Required 
Dose per 
day 
Genetic 
Barrier 
IC50 
(nM) 
Genotypes 
Boceprevir VICTRELIS
™ Merck 
FDA/E
MA 
approve
d 
Linear 800 mg 
TID 
Low 600 1,2 
Telaprevir 
 
INCIVO™ 
Janssen 
 
FDA/E
MA 
approve
d 
Linear 1125 mg 
BID  
Low 300 1,2 
Simeprevir 
 
OLYSIO™ 
 
FDA/E
MA 
approve
d 
 
Macrocycli
c 
150 mg QD Moderat
e 
1-10 1,2,4,5,6 
Faldaprevir 
 
 
BI-201 135 
Boehringer 
Ingelheim 
 
3 
 
 
2 
Macrocycli
c 
120 mg or 
240mg 
QD 
240 mg QD 
Moderat
e 
1-10 1,2 
Danoprevir 
 
Roche 2 Macrocycli
c 
200/r mg 
BID 
100/r mg 
BID 
50/r mg 
BID 
100/r mg 
BID 
Moderat
e 
1-10 1,2,4 
MK5172 Merck 2 Macrocycli
c 
100 mg QD High 1-10 1,2,4,5,6 
Sovaprevir 
ACH-1625 
Achillion 
 
2 Macrocycli
c 
200-800mg 
QD 
Moderat
e 
1-10 1 
Asunaprevir BMS 2 Macrocycli
c 
200-600mg 
BID 
600mg BID 
+ 
Daclatasvir 
60mg QD 
Moderat
e 
1-10 1,4 
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Table 3. HCV Entry Inhibitors. This table shows the different host targets, the 
corresponding examples of inhibitors and the stage of development of those inhibitors (72).  
Target Examples of compounds Stage of development 
CD81 (Cluster of 
Differentiation 81) 
Anti-CD81 mAbs 
Imidazole based compounds 
Mouse model 
Cell culture 
SR-BI (Scavenger 
Receptor – BI) 
ITX5061   
Anti-SR-BI mAbs  
Serum amyloid A 
Phase I/IIa  
Mouse model 
Cell culture 
CLDN1 (Claudin – 1) Anti-CLDN1 mAbs Cell culture 
EGFR (Epidermal Growth 
Factor Receptor) 
Erlotinib Phase I/IIa 
NPC1L1 (Neimann-Pick 
C1-Like 1 gene) 
Ezetimibe Mouse model 
TfR1 (Transferrin 
Receptor Protein 1) 
Anti-TfR1 mAbs Cell culture 
Post-attachment Flavonoids Cell culture 
Fusion/internalization PS-ON (Phosphorothioate 
oligonucleotide) 
Arbidol 
Mouse model  
Cell culture 
Cell culture  
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Chloroquine 
Silymarin 
Cell culture 
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12. Figures 
Figure 1. HCV entry mechanism. LDL-R and Glycosaminoglycan plays the initial role 
by mediating the attachment of HCV associated with liporptoeins to CD81 which then 
interact with SR-BI triggering HCV movement to the tight junction proteins; claudin-1 
(CLDN1) and occluding (OCLN) followed by clathrin mediated endocytosis (11, 12). 
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Figure 2. Model for HCV virion assembly. Based on current evidence, assembly 
initiates on the cytosolic side of the ER membrane (A), and complete maturation occurs 
in the ER lumen (B) prior to release from the cell (24).  (RC: Replicase Complex, LVP: 
Lipo-Viro-Particles, MTP: Microsomal Triglyceride Transfer Protein) 
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Figure 3. Worldwide HCV prevalence 
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Figure 4. HCV Genome. HCV genome is a 9.3 kb polyprotein divided into 3 
structural proteins and 7 non-structural proteins (75).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
Figure 5. The E2c crystal structure resolved by Kong et al. This figure shows the 
structure of the HCV envelope glycoprotein E2 core bound to the neutralizing 
antibody AR3C (PDB ID: 4MWF) (38). 
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Figure 6. The crystal structure of HCV E2 resolved by Khan et al. This figure 
shows the structure of the E2 core domain in complex with an antigen-binding 
fragment (Fab) at 2.4 Å resolution. The E2 core has a compact, globular domain 
structure, consisting mostly of β-strands and random coil with two small α-helices. 
The strands are arranged in two, perpendicular sheets (A and B), which are held 
together by an extensive hydrophobic core and disulphide bonds. (PDB ID: 4NX3) 
(39) 
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Figure 7. Role of CD81 in disrupting HCV-induced immune functions (46). During 
HCV infection, HCV E2 glycoprotein interacts with CD81 at the cell surface of different 
immune cells which in turn leads to B cell activation, aggregation, and increased survival. 
On the other hand, the interaction of HCV E2 with CD81 on T leads to the activation of 
protein tyrosine kinase Lck. This interaction leads to the production of RANTES, a ligand 
for the CCR5 receptor and which upon ligation to CCR5 at the surface of pDCs leads to 
its internalization prevents its migration from infected tissues to lymph nodes. The direct 
interaction of HCV E2 with CD81 at the surface of pDCs leads to a decreased secretion 
of IFN in addition to impaired maturation, proliferation and survival of these cells. HCV 
infection causes an impairment of NK cell functions. The role of CD81 in NK cell-altered 
function could lead to a decreased IL-12- dependent IFN-γ secretion and an increased 
secretion of IL-8. 
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Figure 8. Different classes of HCV drugs targeting different parts of the HCV 
genome. The main 3 classes of drugs that are currently studied are protease 
inhibitors, NS5A inhibitors and polymerase inhibitors which are either nucleoside or 
non-nucleoside polymerase inhibitors (50). 
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B) Malaria 
1. History 
Malaria is considered one of the major parasitic diseases which is transmitted by 
female Anopheles mosquito. It is caused by protozoan parasites belonging to the genus 
Plasmodium (1). Malaria in human is caused by four types of Plasmodium sp. which are: 
Plasmodium malariae, Plasmodium ovale, Plasmodium vivax and Plasmodium 
falciparum. Plasmodium falciparum and Plasmodium vivax are the two major species 
involved in the global malaria burden (1). Malaria infection starts by the invasion of the 
parasite into the hepatocytes (liver stage) followed by invading the red blood cells of the 
host (blood stage) (figure 1).   
Malaria was productively studied since the 1880. Plasmodium falciparum has 
existed for 50,000–100,000 years but the population size of the parasite increased only 
since 10,000 years ago (2). The causative agent of malaria was discovered by Charles 
Laveran (3). He discovered it through examining the blood smears of infected patients in 
1884 (3, 4). In 1898, Scottish physician-Sir Ronald Ross, was able to reveal the complete 
life cycle of malaria and proved the vector was a mosquito. He was awarded the Nobel 
Prize based on his work in 1902 (5). Malaria antigen was detected in skin and lung samples 
of Egyptian mummies in the years 3200 and 1340 BC (6,7). 
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2. Diagnosis 
Malaria is diagnosed mainly by the microscopic examination of the blood film to 
view sporozoites and merozoites. Other techniques used are antigen-based rapid 
diagnostic tests (RDT) (8, 9).  The immune chromatographic tests (ICT) for the detection 
of malaria are based on the same concepts of Enzyme Linked Immunosorbent Assay 
(ELISA) and detect antibodies in blood or other body fluids (10, 11). 
Malaria doesn’t yield characteristic symptoms when infecting a person. 
Accordingly, when there a is suspicion of infection, recent travel history, fever, low 
number of platelets, enlarged spleen, and higher-than-normal levels of bilirubin in the 
blood combined with a normal level of white blood cells might help decide whether there 
is a risk of malaria infection or not (12). 
3. Current treatment 
The treatment of Malaria depends on the type and severity of the disease. 
Artimisinin-combination therapy (ACT) is considered the first-line therapy for 
uncomplicated Plasmodium falciparum malaria worldwide (13). To date, there is no 
enough data to help observe the emerging problem of ACT-resistant strains, hence there 
is a need to study the dynamics of parasite clearance in people treated with ACT in order 
to be able to confirm the emergence of artemisinin resistance (14). 
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4. CD81: Malaria host receptor 
The life cycle of Malaria starts through injection of sporozoites into the host’s skin 
by female Anopheles mosquitoes. The sporozoites are motile due to possessing 
actonyosin motor machinery which help them move in the blood stream, entering the liver 
in and transform to liver stages in the hepatocytes. The motile sporozoites enter the blood 
stream and, upon reaching the liver, transform into liver stages (14). They invade hepatic 
parenchymal cells and produce exo-erythrocytic forms (EEFs) through a period of asexual 
reproduction followed by infecting the erythrocytes causing the malaria disease (15, 16).  
Silvie et al. (16) showed that CD81 is involved in the hepatic development of 
Plasmodium falciparum and Plasmodium yoelii in the liver cells and in CD81-deficient 
mouse hepatocytes, Plasmodium yoelii can’t initiate the infection process. Additionally, 
they were able to show that antibodies against human and mouse CD81 blocked the 
infection with Plasmodium falciparum and Plasmodium yoelii respectively. They were 
able to prove that CD81 is involved in the entry stage of sporozoites into the liver though 
being linked to the formation of parasitophorous vacuole which one of the major steps 
needed for the sporozoites to transform to EEFs.   
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6. Figures 
Figure 1. Malaria Life cycle. The life cycle of malaria is divided into 3 significant 
stages; The Exo-erythrocytic stage /Liver stage (A), the erythrocytic stage/Blood stage 
(B) and the sporogenic stage which takes place in the gut of the female Anopheles 
mosquito followed by its salivary gland (Center of Disease Control and Prevention) 
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C) Summary and Conclusion 
HCV and Malaria are two challenging infectious diseases due to the genomic 
diversity and not having the full picture of the mechanism of entry into the host cells in 
case of the former and the emerging resistant strains against the currently available 
medications for the later. Several research groups identified important residues in CD81-
LEL involved in the infection of both HCV and malaria and their internalization into 
hepatocytes (16, 43, 44). Targeting the identified residues would help develop promising 
drugs for treating HCV and malaria.  
Additionally, HCV E2 core crystal structure was recently resolved (PDB ID: 
4MWF) (figure 5) (38). This would facilitate creating a reliable homology model for the 
whole HCV E2 protein that could be used to identify drug leads that blocks HCV E2: Host 
factors interaction.  
Targeting HCV to develop drugs is advantageous because the side effects that 
might be caused when using drugs that target host receptors are unpredictable. On the 
other hand, targeting the host receptors to develop new classes of drugs is better when 
dealing with the continuous mutation of HCV and the resistance it develops against direct 
acting antivirals.  
Different approaches could be used to generate promising drugs against HCV and 
malaria. Generating selective high affinity ligands is one of them where it is mainly 
linking to ligands that were found to bind to the target protein together to increase their 
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binding affinity and it might reach a nanomolar binding affinity. Another one is to identify 
a drug lead, optimize its chemical QSAR to be more effective with less side effects. Also, 
finding different analogues to the drug lead, testing them and creating a library would be 
a potential tool in the drug discovery process.   
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CHAPTER III 
 IDENTIFICATION OF LIGANDS THAT TARGET HCV E2-BINDING SITE 
ON CD81-LARGE EXTRACELLULAR LOOP 
This chapter was published: Olaby, R. A., Azzazy, H. M., Harris, R., Chromy, B., 
Vielmetter, J. and Balhorn, R. (2013).Identification of ligands that target the HCV-E2 
binding site on CD81. J. Comput. Aided Mol. Des. 27, 337-346. 
Objectives 
The purpose of this study was to screen a library of 10,000 compounds to identify 
virtual screening hits that binds to significant sites on CD81-LEL. Additionally, it aimed 
at testing the top virtual screening hits experimentally using Lab on a chip techniques to 
help identify possible ligand candidates to be incorporated into a SHAL prototype. The 
computational biology work was done at Scripps Research Institute, Dr. Arthur Olson’s 
Molecular Graphics Laboratory, the dual polarization interferometry binding assays were 
done at UC Davis at Dr. Brett Chromy’s lab, and the surface plasmon resonance binding 
assays were done at Caltech at Dr. Jost Vielmetter’s protein expression center.   
1. Introduction 
The World Health Organization has estimated that approximately 3% of the world 
population has been infected with Hepatitis C virus (HCV) and that more than 170 million 
of these individuals are at risk for developing liver cirrhosis or cancer (1). The lack of 
effective treatment or prophylactic vaccines makes HCV a serious public health problem. 
The virus is a blood borne pathogen that is transmitted mainly through transfusions and 
hemodialysis. During HCV replication, the post-translational processing and cleavage of 
the virus polyprotein produces ten structural and non-structural proteins. The crystal 
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structures that have been determined for a number of these proteins are being used to 
facilitate both drug and vaccine development (2-9). 
Several cell surface receptors have been suggested to play a role in HCV entry into 
hepatocytes (10). These include LDL-R, heparan sulfate (11), scavenger receptor class BI 
(SR-BI) and CD81 (12,13). Pileri et al. was the first to identify CD81, a 26 kDa protein 
that belongs to the tetraspanins super family, as an important HCV receptor (14). While 
this protein mediates the invasion of hepatocytes by HCV, it is also widely expressed in 
both lymphoid and non-lymphoid tissues. CD81 contains six structural domains, four of 
which are trans membrane domains and two are hydrophilic extracellular domains that 
make up the large and small extracellular loops (15).  
One reason CD81 has become such an important target for drug development is 
because the large extracellular loop of CD81 (CD81-LEL) has been shown to bind to the 
HCV E2 glycoprotein (16-19). Zhang et al. discovered that CD81-LEL is also important 
for efficient replication of the HCV genome (18). In addition, the E2:CD81-LEL 
interaction has been reported to induce several immuno-modulatory effects, including a 
co-stimulatory signal in naive and antigen-experienced T cells in vitro that leads to 
production of the pro-inflammatory cytokine α-interferon. This suggests that the 
E2:CD81-LEL interaction may play a role in T-cell-mediated liver inflammation and may 
contribute to liver damage. The interaction of these two proteins also appears to down 
regulate T-cell receptors and suppress the activity of natural killer cells (18). 
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CD81’s participation in cell invasion and its contribution to liver damage make it 
an important target for new anti-HCV therapeutics. Some of the first inhibitors designed 
to block the E2:CD81-LEL interaction were CD81 mimics developed by 
VanCompernolle et al. (20). Small molecules were designed to mimic the solvent exposed 
hydrophobic ridge of helix D in the CD81-LEL domain and were found to bind HCV E2 
reversibly and to competitively block the binding of E2 to CD81 (20). This was the first 
direct demonstration that CD81 is an important receptor in HCV entry (20). In addition, 
the mutational studies conducted by Higginbottom et al. (17) and Drummer et al. (19) 
identified the key amino acid residues that contribute to the E2:CD81-LEL interaction.  
Kitadokoro et al. determined the 3D structure of CD81-LEL using X-ray 
crystallography, and two different crystal forms of CD81-LEL (PDB codes 1G8Q and 
1IV5) were reported (21,22). In the 1G8Q structure the C and D helices form a cleft-like 
motif within the E2 binding site, a large cavity considered to be an excellent target site for 
inhibitor development. The 1IV5 conformation, in contrast, was considered to be a closed 
form of the CD81 structure in which this cleft is absent. Ligands binding to the closed 
conformation would involve interactions with 1IV5 in more shallow surface exposed sites 
than those present on 1G8Q (22). Molecular dynamics studies performed by Neugebauer 
et al. (23) have been used to suggest that the 1IV5 structure may be the physiologically 
relevant conformation. This conclusion has been attributed in part to the closure of the 
cleft in 1G8Q that occurred during a 50 picosecond molecular dynamic simulation.  The 
1G8Q conformation with the open cleft was also considered to be less stable because more 
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amino acid residues were found to be outside the favored energy region of the 
Ramachandran plot. Further analysis of the two structures suggested that the cleft 
observed in the open 1G8Q conformation might represent a distortion in the structure of 
the protein induced by crystal packing. In the closed 1IV5 structure, two of the four alpha 
helices (C and D) in CD81-LEL were observed to form a helix bundle with the two other 
helices (A and B) of an adjacent molecule in the lattice. In the 1G8Q form, a different 
interaction was observed between helices that appeared to distort the structure of the 
protein and create the cleft (22).    
The discovery of these two distinct crystal forms of the CD81-LEL protein with 
very different surface structures in and around the E2 binding site has complicated the 
process of inhibitor development. The “open” form has multiple cavities surrounding the 
key amino acids, while the surface of the “closed” form has many fewer and shallower 
sites where ligands might bind. While it has been suggested that the closed form may be 
more stable than the open form, Neugebauer et al. (23) also indicated that the C and D 
helices exhibit a certain degree of flexibility that might make it possible to identify small 
molecules that fit inside the cleft between these two helices and block the interaction 
between CD81 and E2.   
In an effort to test that possibility, we have used AutoDock and AutoLigand to 
screen a library of 10,000 small molecules in silico and identify ligands predicted to bind 
to two sites on the open conformation of CD81-LEL, the large cleft between the C and D 
helices and a smaller cavity located nearby. Both cavities are located within the E2 
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binding site and in close proximity to five of the amino acid residues reported to contact 
E2. Experimental methods have been used to test the best virtual screening hits for binding 
to a recombinant form of CD81-LEL, and a set of new small molecule drug candidates 
have been identified that bind to the protein. One of these compounds has been found to 
block E2 binding to CD81-LEL. Fragment-based extension methods will be used to create 
second-generation lead compounds from a number of these molecules. Others will be 
linked together to create selective high affinity ligands (SHALs) (24) that target the E2 
binding site on CD81-LEL and block HCV invasion. 
2. Materials and Methods 
2.1. Preparation of CD81-LEL Structure and Prediction of Binding Sites  
The AutoDock suite of programs developed by Dr. Arthur Olson’s molecular 
graphics laboratory at the Scripps Research Institute was used to analyze the large 
extracellular domain of our target protein CD81, prepare surface grid maps, and dock a 
library of small molecules into cavities located in the vicinity of amino acid residues 
known to participate in E2 binding (25-29). 
The coordinates for the crystal structure of the open conformation of CD81-LEL 
(PDB ID: 1G8Q) were obtained from the Protein Data Bank (PDB). AutoDock Tools 
(ADT) 1.5.6 (25-28) was used to delete water molecules, add polar hydrogens, assign 
Gasteiger charges, and create grid bounding boxes with a 1 Å spacing for use with 
AutoLigand and a 0.375 Å spacing for use with AutoDock 4.2. AutoGrid 4.2 was used to 
pre-calculate grid maps of interaction energies for various atom types and create the map 
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files that were used by AutoLigand to predict the CD81-LEL binding sites and by 
AutoDock for docking. AutoLigand was then used to rapidly scan the protein for high 
affinity binding pockets and identify the optimal volume, shape, and best atom types for 
each binding site.  
The CD81-LEL protein was scanned by AutoLigand using fill sizes from 10 to 
210 fill points.  During this process, the structure (amino acid re -carbon 
backbone) was kept rigid. The constructed grid box enclosed the entire protein with 
dimensions of 40 Å by 18 Å by 38 Å and was centered on 3.144, 34.966, and 15.812 in 
the protein frame of reference.  Five potential ligand binding sites were identified on the 
open CD81-LEL structure (PDB code 1G8Q). Two sites located adjacent to amino acid 
residues critical for E2 binding were selected for docking. 
2.2. Virtual Screening 
AutoDock 4.2 (25-28) was used to perform virtual screening runs using a subset 
of the ZINC small molecule database containing 10,000 molecules taken from the 
National Cancer Institute-Diversity Set II (NCI_DSII), Sigma, and Asinex libraries. The 
parameters were set at 100 for the number of genetic algorithm (GA) runs, 150 as the 
population size, and a maximum number of generations of 25000. The Lamarckian genetic 
algorithm in AutoDock was used to perform the docking experiments (30). Docking 
results were sorted by the lowest binding energy in addition to specific ligand selection 
criteria that would facilitate the design and synthesis of the best SHALs. The virtual 
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screening runs were performed using the National Biomedical Computation Resources 
(NBCR) computer cluster (31). Vision (32) was used to construct the computational 
workflows that were used for virtual screening on the NBCR cluster. The list of small 
molecules predicted to bind to each site (~ 350 compounds) was ranked according to their 
predicted free energy of binding, and the molecules with the lowest free energies were 
further screened manually to identify ~120 of the best ligand candidates for experimental 
testing.  
2.3. Ligand Evaluation 
Several criteria were considered as we examined the structures of each of these 
~120 small molecules and selected a subset for subsequent experimental testing and for 
use in the design of second-generation lead compounds and SHALs. All the molecules 
selected could be purchased from chemical suppliers or obtained from the Developmental 
Therapeutics Program at NCI. During the initial examination of the list of ligands 
predicted to bind to each site by AutoDock, only molecules containing a free carboxyl 
group or an amino group (or one of each) were selected. In the most highly ranked cases, 
these amino or carboxyl groups were not buried in a cavity nor did they interact with the 
protein surface. They were exposed to solvent and were predicted by AutoDock to bind 
to the protein with the functional group pointed in the general direction of the second 
ligand binding site. Such molecules could be easily linked together through their amino 
or carboxyl groups to create SHALs (24). Preference was given to ligands that were 
predicted to form multiple contacts with atoms or amino acid residues in or around the 
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perimeter of the targeted cavities. Molecules that were highly hydrophobic, highly 
charged, known to be toxic, exist in more than one form (such as enol-keto forms), or 
contained disulfide bonds were avoided. After manually filtering the ligand sets to remove 
the molecules that did not meet these criteria, the predicted binding energy was used to 
identify the top hits.  Thirteen molecules predicted to bind to Site 1 were selected from 
this group for experimental testing and 23 molecules were selected for Site 2. Small 
amounts (10mg) of these 36 compounds were then obtained from the National Cancer 
Institute (Diversity Set II small molecule library) and tested experimentally for binding to 
the CD81-LEL protein. 
2.4. Surface Plasmon Resonance 
 SPR analysis was performed using a Biacore T200 workstation (GE Healthcare, 
NJ, USA). A recombinant form of the CD81-LEL protein with a GST tag (generously 
provided by Dr. Shoshana Levy, Stanford University) was used to determine, using well 
established experimental technique, if the ligands bound to the protein. Briefly, 10 µM 
CD81-LEL-GST diluted into 10 mM Na-Acetate buffer pH 4.5 was immobilized for 15 
min at a flow speed of 5 µl/min onto a CM5 sensor chip using amine-coupling (EDC-
NHS).  Approximately 20,000 RU of protein were immobilized on the chip.  The ligands 
were prepared as 600 µM solutions in PBS-0.05% Tween-80 (the running buffer) and they 
were introduced to the protein using a pre-programmed 3 minute association and 1 minute 
dissociation interval.  
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The binding affinity of selected ligands were estimated using data collected from 
a series of SPR binding experiments conducted at different ligand concentrations. To 
obtain the kinetic and affinity data needed to estimate the Kd, the original ligand sample 
was diluted serially with running buffer to produce seven different ligand concentrations: 
1024 µM, 516 µM, 256 µM, 128 µM, 64µM, 32 µM and 0 µM. Data were fitted using a 
monovalent binding model.  
2.5. Dual Polarization Interferometry (DPI) Analysis 
DPI analyses were performed using an AnaLight 4D workstation (Farfield Group, 
Manchester UK). The recombinant CD81-LEL was immobilized onto a Thiol AnaChip 
using Sulfo-GMBS as a cross-linker in PBS running buffer. Non-specific sites were 
blocked with digested casein. TRIS was used to cap the cross-linker, blocking any 
additional amines from covalently binding to the cross-linker on the chip surface. Ligands 
were prepared as 20 mM stock solutions in dimethylsulfoxide (DMSO). Each ligand was 
diluted to a final concentration of 500 µM in PBS just prior to injection (final DMSO 
concentration was 2.5%). PBS and DMSO mixed in the same ratio were used as a blank. 
Data collection and analysis were performed using the AnaLight Resolver.  
A subset of the ligands identified to bind to CD81-LEL were also tested to 
determine if they might block the HCV E2 protein from binding to CD81-LEL using DPI. 
In these experiments, a recombinant form of the CD81-LEL protein was immobilized on 
the chip and unreacted cross-linker was blocked as described above. Recombinant HCV 
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E2 protein (Immune Technology Corp, New York, NY) was then injected to determine 
the magnitude of the binding response when E2 bound to CD81-LEL in the absence of 
the ligand. To evaluate the effect of a ligand on E2 binding to CD81-LEL, the same 
experiment was repeated except that the E2 protein was premixed with the ligand at a final 
ligand concentration of 500 µM. If the ligand inhibits E2 binding to CD81-LEL when the 
mix of E2 and the ligand are added to the chip, the DPI binding response in the presence 
of the ligand should be less than the response in the absence of the ligand. If a reduction 
in E2 binding is observed by DPI, the magnitude of the inhibition can be calculated using 
the binding responses for the ligand, the E2 protein and a mixture of the E2 protein and 
the ligand. 
3. Results and Discussion 
3.1. Target Regions on CD81-LEL 
In this study we used the crystal structure of the open CD81-LEL conformation as 
the target for the virtual screening runs performed using AutoDock to identify small 
molecule ligands predicted to bind to cavities that encompass or are located near known 
E2 contact residues. Based on mutation studies, Higginbottom et al. (17) identified four 
residues that were considered to be essential for the HCV E2 protein to bind to CD81-
LEL. The Asp196Glu mutation in CD81 was observed to reduce binding to E2. In addition 
mutations Phe186Leu and Glu188Lys inhibited binding of CD81 to E2, whereas the 
Thr163Ala mutation enhanced their interaction (17). Drummer et al. (19) also examined 
the binding site, which was estimated to cover approximately 806 Å2 of the CD81-LEL 
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surface, and identified three additional amino acid contacts, Ile182, Asn184, and Leu162 
(19) (figure 1). We used these seven residues as markers to identify the best regions on 
the CD81-LEL protein surface to target when designing inhibitors to block the E2:CD81 
interaction.  
3.2. The AutoLigand Fill Points and Energy Plot Analysis 
AutoLigand was used to analyze the surface of CD81-LEL and select the best 
ligand binding sites. Five binding sites were identified as potential targets by plotting the 
total energy per volume (Kcal/mol ) for the fill points generated against the volume of the 
filled site and picking those sites with the lowest values.  Figure 2 shows the data from 
each fill generated at different starting points on the surface using increasing numbers of 
fill points to fill larger and larger volumes.  The fill volumes with less than 100 Å3 are 
small cavities within the protein structure that could be water or ion binding sites and were 
not considered suitable drug targets.  The open diamonds are the values for the fills near 
amino acid Asn184, one of the five key residues shown previously to interact with E2. 
The best fill for the site in this region, -0.165 Kcal/mol Å3, was obtained using 180 fill 
points.  As more points were used and the volume of the cavity increased, the predicted 
free energy of binding became less favorable. 
One site predicted by AutoLigand to be an excellent small molecule binding site 
was located in a region that contained five of the CD81 amino acid residues (Ile182, 
Phe186, Asn184, Glu188, Asp196) (19) that have been shown by others to interact with 
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E2 (figure 3a). This is a large cavity located between the C and D helices that is only 
present in the open conformation of CD81-LEL. A second group of fill points was 
generated for a neighboring cavity located on the opposite side of the protein (figure 3b). 
The fill points generated for these two sites were predicted to have the lowest interaction 
energy of all the sites identified on the open conformation of CD81-LEL. Consequently, 
these two sites were selected as the primary sites for use in small molecule docking.  
3.3. Docking and Analysis of Ligands Predicted to Bind to the Selected Sites 
 Docking runs were performed for the sites selected on CD81-LEL using the NCI 
Diversity Set II, Sigma, and Asinex libraries of small molecules. The list of ligands 
predicted to bind to each site were ranked according to binding energy and how well the 
ligand’s atoms mapped onto the fill points for the site. In addition to the fill points defining 
the rough shape of ligands that would fit best within the cavity, specific fill points were 
also color coded to identify particular atoms (C,H,N,O) in the ligand that would interact 
optimally with the surface of the protein in the regions surrounding the ligand (figure 4). 
The fill points predicted for the site shown in Figure 4a are colored red for hydrogen 
acceptors such as oxygen or nitrogen, blue for hydrogen, or grey for carbon. One of the 
better ligands predicted to bind to this site (figure 4b) has atoms that superimpose well 
with the fill point map (figure 4c). While the superimposition does not need to match 
perfectly, the points of contact on the protein are considered to be good if the majority of 
the different atom types in the molecule (75-80%) approximate the same location as the 
fill points. Such ligands would be expected to form multiple contacts/interactions with the 
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protein (such as hydrogen bonds, salt bridges, van der Waals interactions) and should bind 
more tightly than other ligands predicted to make only one or two contacts.  
3.4. Experimental Confirmation of Ligand Binding  
 A total of 36 ligands were tested experimentally using surface Plasmon resonance 
(Biacore T200 instrument) to identify which of the molecules predicted to bind to Sites 1 
and 2 on CD81 actually bind to a recombinant form of the protein (CD81-LEL). Twenty-
six of the molecules provided a positive change in response units (RU) upon introduction 
to a chip containing the immobilized protein (Table 1), indicating the ligands bound to the 
protein. The measured responses for the ligands that bound varied from 2.3 to 78.4 RU. 
Those ligands providing the largest responses tended to be molecules that were predicted 
to bind more deeply inside cavities in Site 1 (ligands 30930, 98026, 7438, 5069) or Site 2 
(ligands 78623, 127947, 16631, 38743). Control experiments were performed to confirm 
that the recombinant form of CD81-LEL we used in these experiments had the correct 
structure. In these experiments, the CD81-LEL protein was immobilized on a chip and 
then DPI was used to show the HCV E2 protein recognized and bound to the immobilized 
CD81-LEL (Table 2).  
Six of the more interesting ligand candidates (three predicted to bind to Site 1 and 
three predicted to bind to Site 2) were further tested to confirm they bind to CD81-LEL 
using DPI. The results, shown in Figure 5, showed that all six ligands bound to the protein. 
The relative rank in strength of binding of the Site 1 and 2 ligands, as determined by DPI, 
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were also similar to the ranking obtained by SPR and the free energy of binding predicted 
by AutoDock for the majority of the ligands. Ligands 1 - 4 exhibited binding responses 
that were stronger than or equivalent to the binding observed for benzyl salicylate (0.58 
radians, see Figure 5), a small molecule reported previously to block E2 binding to CD81 
(33). Benzyl salicylate was identified by Holzer et al. (33) by performing a similar virtual 
screen of small molecules (using a different set of databases) to the cleft we have referred 
to as Site 1 in the open conformation of CD81-LEL. Thirty-seven analogs of benzyl 
salicylate were subsequently synthesized by Holzer et al. (33) in an effort to enhance the 
inhibitory activity of benzyl salicylate, but none of the analogs proved to be a better 
inhibitor than parent compound benzyl salicylate.  
For some ligands, significant differences were observed in the actual binding 
responses obtained by SPR and DPI. As one example, Ligands 1, 2 and 5 had a very 
similar binding response when tested by SPR, but these ligands exhibited different 
responses when tested by DPI. One reason for this observed difference in the DPI response 
might relate to conformational changes in the protein that occur when the small molecules 
bind.  The change in radians measured using DPI when a ligand binds to a protein is 
known to result from a combination of two effects: 1) the resulting increase in mass and 
volume when the ligand binds to the protein on the surface of the chip and 2) a 
conformational change in the protein induced by the binding of the ligand. Small 
molecules binding in deeper cavities would be expected to have more and stronger 
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contacts with the protein than ligands sitting exposed to solvent in shallow cavities or 
surface binding sites. 
Those molecules predicted by AutoDock to have the lowest free energy of binding 
also exhibited the largest DPI radians change and SPR response. The collective data 
provided by the AutoDock free energy prediction, SPR, and DPI binding assays allowed 
us to estimate and categorize the relative strength of the ligand’s binding to CD81-LEL 
as strong, moderate or weak. Within the set of six ligands shown in Figure 5, Ligands 1, 
2 and 4 exhibit the strongest binding, followed by ligands 5 and 6, which are categorized 
as moderate binders. Ligand 3 appears to be the weakest binder in the group. Additional 
SPR analyses performed using a series of Ligand 1 concentrations (figure 6) provided an 
estimated Kd of 201µM for an affinity fit of Ligand 1 binding to the recombinant CD81-
LEL protein.  
3.5. Effect of Ligand 3 on in vitro Binding of HCV E2 Protein to CD81-LEL 
 Competition experiments were also performed to determine if selected Site 1 or 
Site 2 ligands might block E2 binding to CD81-LEL. The two strongest binders in the Site 
1 group shown in Figure 5 did not block E2 binding to CD81-LEL. Ligand 3 (689002), 
on the other hand, was observed to reduce E2 binding to CD81-LEL by 40% (Table 2). 
The magnitude of the reduction in the binding response in the presence of Ligand 3 is 
consistent with Ligand 3 having an EC50 greater than 500 µM and being slightly less 
effective than benzyl salicylate in inhibiting E2 binding to CD81-LEL. This result not 
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only confirms that Ligand 3 binds within the E2 binding site on CD81-LEL, but it also 
identifies a small molecule that could prove useful as an early stage drug lead in the 
development of therapeutics that block HCV invasion.  
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5. Figures 
Figure 1. Amino acid residues that participate in HCV E2 binding to CD81-LEL The 
colored residues are amino acids that have been identified by Higginbottom et al. (17) and 
Drummer et al. (19) to contribute to the binding of the HCV protein E2 to CD81-LEL. 
The structure shown is the monomer of the open conformation of CD81-LEL (PDB ID: 
1G8Q). (a) Front view of the protein showing the four contact residues Leu162 (blue), 
Ile182 (green), Asn184 (orange), and Phe186 (red). (b) Back side of the CD81-LEL 
protein showing the other three contact residues Thr163 (yellow), Glu188 (cyan) and 
Asp196 (magenta). This figure was prepared using AutoDock Tools version 1.5.6. 
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Figure 2. Predicted free energy data for ligand binding sites identified on the surface 
of CD81-LEL by AutoLigand. This figure was generated by plotting the total energy per 
volume versus the volume of each fill made from different amounts of fill points.  The 
different symbols depict the fills that start in different locations within the five 
cavities/sites identified by AutoLigand. Note that there are more than five sets of symbols 
because some symbols represent fills starting in different locations within the same site 
(e.g. the large cavity called Site 1).  The most efficient fills are those that have the lowest 
total energy per volume using the smallest volume. The fill points enclosed in the boxes 
labelled Site 1 and Site 2 correspond to the fills used for docking. This figure was prepared 
using AutoDock Tools version 1.5.6.  
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Figure 3. Two ligand binding sites identified by AutoLigand on the open 
conformation of CD81-LEL (PDB ID: 1G8Q) These two sites were selected as docking 
targets based on their proximity to the amino acid residues that contact E2 (identified on 
the molecular surface by blue, yellow, green, orange, cyan, red and magenta colors; see 
Figure 1 legend for residue numbers) and the low free energy (high affinity) predicted for 
ligands that would bind in this site. (a) The green spheres fill Site 1 and define its location, 
the large cavity located between the C and D helices predicted by AutoLigand to be the 
best binding site. Ligands binding to this site would bind very close to the majority of the 
amino acids that participate in binding to E2. The green spheres correspond to the open 
diamond fill points in Figure 2 located between 500 and 600 Å3. (b) The brown spheres 
show the location of a second binding site, Site 2, predicted by AutoLigand on the 
opposite side of the protein. Ligands binding to this site should also contribute to the 
disruption of E2 binding. The brown spheres correspond to the black square fill points 
shown in Figure 2 located between 550 and 650 Å3. This figure was prepared using 
AutoDock Tools version 1.5.6.  
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Figure 4. AutoLigand Analysis of the Site 1 ligand binding site AutoLigand fill points 
not only identify cavities on the surfaces of proteins, but they also predict the structural 
features of ligands that would bind with the best affinity and selectivity to the protein at 
these sites. (a) The fill points provided by AutoLigand define the rough shape of ligands 
that would fit best into the Site 1 cavity. Individual or groups of fill points are also color 
coded (gray for carbon, light blue for hydrogen, and red for hydrogen acceptors oxygen 
and nitrogen) to identify particular atoms in the ligand that would interact optimally with 
the protein’s atoms or functional groups in the regions surrounding the ligand. (b) Ligand 
1 is shown bound to Site 1 on CD81-LEL in the location and orientation predicted by 
AutoDock.  (c) The superposition of fill points (small spheres) provided by AutoLigand 
and the actual atom types in Ligand 1 (large spheres) is high (75-80%) indicating that this 
ligand should bind well in this particular site. Note that the amino acid residues that 
contact E2 shown in Figure 1 are also shown in these figures using the same color-coding. 
This figure was prepared using AutoDock Tools version 1.5.6.  
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Figure 5. Confirmation of ligand binding to CD81-LEL using DPI Six of the ligands 
that were found to bind to CD81-LEL by SPR analysis were selected and tested by a 
second method, DPI, to confirm they bind to CD81-LEL. The results show that all six 
ligands bind to the protein. The molecules are listed according to the assessed quality of 
the ligand and its interaction with CD81-LEL using AutoDock’s predicted free energy of 
binding and the DPI and SPR binding data. The relative rank in strength of binding of the 
Site 1 and 2 ligands, as determined by DPI, were also similar to the ranking obtained by 
SPR and the free energy of binding predicted by AutoDock. Ligands 1 - 4 exhibited 
binding responses that were stronger than or similar to the binding observed for benzyl 
salicylate, a small molecule reported previously to block E2 binding to CD81 (33). 
Criteria used to define the quality of the ligands are: Strong - makes more than 5 contacts 
with protein, predicted to be selective and not predicted to bind to multiple sites, not too 
hydrophobic in addition to having an in silico binding energy of > -5, DPI binding of > 
0.3 radians and SPR binding response of > 30 Response Units (RU); moderate - makes 4-
5 contacts with protein, hydrophobic interactions contribute to binding in addition to 
having an in silico binding energy of > -3, a DPI binding of > 0.15 radians and SPR 
binding response of > 10; and weak – makes 3-4 contacts with protein in addition to 
having an in silico binding energy of < - 3 , a DPI binding of <0.15  radians and SPR 
binding response of < 10 RU. 
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Figure 6. Binding of Ligand 1 to CD81-LEL as a function of ligand concentration 
This binding experiment was performed using a Biacore T200 as described in the 
Materials and Methods section. Using the data shown, Ligand 1 was estimated to have a 
Kd of ~201µM based on an affinity fit. 
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6. Tables 
Table 1. Experimental analysis of ligand binding to recombinant CD81-LEL. Thirty-
six ligands predicted by AutoDock to bind to Sites 1 and 2 on CD81-LEL were tested 
experimentally using surface Plasmon resonance as described in the Materials and 
Methods section. Ligand code numbers are those assigned by the National Cancer 
Institute. The data, which are the response units generated by the Biacore instrument, are 
shown for only the 26 ligands that were observed to bind. Because the binding 
experiments were performed by passing the same concentration of each ligand 
sequentially across the same protein coated chip, the magnitude of the response can be 
used to provide an approximate ranking of binding strength. Response unit values greater 
than 0 indicate binding.  
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Table 2. DPI competition experiment showing inhibition of E2 binding to CD81-LEL 
by Ligand 3 (689002) and comparing the inhibition to that achieved with benzyl 
salicylate. 
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CHAPTER IV 
 GENERATION OF A SHAL PROTOTYPE (SH7153) USING CD81-LEL AS A 
TARGET 
Objectives 
The aim of this study is to generate a bidentate SHAL prototype (SH7153) and 
test using Surface Plasmon resonance, antibody neutralizing assays and HCV infection 
inhibition assays to determine its inhibitory effects on HCV. The computational biology 
work was done at Scripps Research Institute (USA), Dr. Arthur Olson’s Molecular 
Graphics Laboratory, the surface plasmon resonance binding assays were done at Caltech 
(USA) at Dr. Jost Vielmetter’s protein expression center, and the HCV infections assays 
were done at Institute Pasteur De Lille (France) at Dr. Jean Dubuisson’s lab.   
1. Introduction 
Several steps in the HCV life cycle are being actively targeted to create new drugs 
that block virus invasion, processing of the pro-protein or replication of the viral genome 
(1, 2). CD81 is considered a major HCV receptor that participates in the first step in the 
process – entry of the virus into hepatocytes (3). A number of anti-CD81 antibodies have 
been shown to block viral invasion and protect cells from the HCV cytopathic effect (4). 
Holzer et al. was one of the first to select for and identify small molecules that target this 
entry step (5,6). Two compounds identified in virtual and experimental screens performed 
by this group, benzyl salicylate (5) and terfenadine (6), have been shown to be moderate 
inhibitors of the HCV E2: CD81 interaction. we identified a second cavity within the E2 
binding site adjacent to the large cleft targeted by Holzer et al. (5,6) using AutoLigand (7) 
to search the surface of CD81-LEL near the amino acid residues in CD81 that participate 
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in HCV envelope glycoprotein binding (8, 9). Virtual screening runs were performed 
using AutoDock (10) to identify additional small molecules which might bind to the large 
cavity targeted previously by Holzer et al. and to this new cavity, and 26 of those predicted 
to bind were confirmed experimentally to bind to CD81. One of these ligands, 689002, 
was also shown to block E2 binding (11). New experiments were conducted with the 
ligands predicted to bind to the second cavity have identified another ligand that blocks 
E2 binding to CD81-LEL. We have used these two ligands to design and synthesize a 
prototype (first generation) selective high affinity ligand (SHAL) as a steric inhibitor to 
block HCV E2 glycoprotein binding to CD81.  
2. Materials and Methods 
2.1. Recombinant Proteins, Antibodies and Ligands 
  
 The recombinant HCV E2 glycoprotein was provided by Dr. Joseph Marcotrigiano 
(Rutgers University-NJ/USA), His-CD81-LEL (Bioclone-CA/USA) , JS-81 antibody 
(BD Pharmingen, 551108) and the small molecules were provided by the NIH/NCI 
Developmental Therapeutics Program. 
 
2.2. Dual Polarization Interferometry  
 
DPI analyses were performed using an AnaLight 4D workstation (Farfield Group, 
Manchester UK). The recombinant CD81-LEL was immobilized onto a Thiol AnaChip 
using Sulfo-GMBS as a cross-linker in PBS running buffer (pH 7.4). Non-specific sites 
were blocked with digested casein. TRIS was used to cap the cross-linker, blocking any 
additional amines from covalently binding to the cross-linker on the chip surface. Ligands 
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were prepared as 20 mM stock solutions in dimethylsulfoxide (DMSO). Each ligand was 
diluted to a final concentration of 500 uM in PBS just prior to injection (final DMSO 
concentration was 2.5 %). PBS and DMSO mixed in the same ratio were used as a blank. 
Data collection and analysis were performed using the AnaLight Resolver.  
A subset of the ligands identified to bind to CD81-LEL was also tested to 
determine if they might block the HCV E2 glycoprotein from binding to CD81-LEL using 
DPI. In these experiments, a recombinant form of the CD81-LEL protein was immobilized 
on the chip and unreacted cross-linker was blocked as described above. Recombinant 
HCV E2 glycoprotein (Immune Technology Corp, New York, NY) was then injected to 
determine the magnitude of the binding response when E2 bound to CD81-LEL in the 
absence of the ligand. To evaluate the effect of a ligand on E2 binding to CD81-LEL, the 
same experiment was repeated except that the E2 glycoprotein was premixed with the 
ligand at a final ligand concentration of 500 uM. If the ligand inhibits E2 binding to CD81-
LEL when the mix of E2 and the ligand are added to the chip, the DPI binding response 
in the presence of the ligand should be less than the response in the absence of the ligand. 
If a reduction in E2 binding is observed by DPI, the magnitude of the inhibition can be 
calculated using the binding responses for the ligand, the E2 glycoprotein and a mixture 
of the E2 glycoprotein and the ligand. 
2.3. Surface Plasmon Resonance 
 
SPR analysis was performed using a Biacore T100 workstation (GE Healthcare, 
NJ, USA). A recombinant form of the CD81-LEL protein with a His-tag (Bioclone-
CA/USA) was used to determine the binding affinities of ligands 689002 and 93033 in 
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addition to that of SH7153. Briefly, 10 uM CD81-LEL-His diluted into 10 mM sodium 
acetate buffer pH 4.5 was immobilized for 15 min at a flow speed of 5 ul/min onto a CM5 
sensor chip using amine coupling (EDC-NHS). Approximately 20,000 RU of protein were 
immobilized on the chip. The ligands prepared as 200 uM solutions in PBS-1% DMSO 
(the running buffer) and they were introduced to the protein using a pre-programmed 3 
min association and 1 min dissociation interval. The binding affinities of selected ligands 
were estimated using data collected from a series of SPR binding experiments conducted 
at different ligand concentrations. To obtain the kinetic and affinity data needed to 
estimate the Kd, the original ligand sample was diluted serially with running buffer to 
produce five different ligand concentrations: 200, 66.6, 22.2, 7.41, 2.47 and 0 uM. Data 
were fitted using a monovalent binding model. 
2.4. Solid phase synthesis of SH7153 and its analogues 
 
Unless otherwise stated, all reagents and solvents were obtained from commercial 
suppliers and used as received. 2Chlorotrityl chloride resin (100-200 mesh, 1% DVB, 1.2 
mmol/g loading density) and all Fmoc-protected amino acids were obtained from 
Novabiochem Inc. Fmoc-8-amino-3,6dioxactanonic acid (Fmoc-mini-PEG) was 
purchased from Peptides Int. (Louisville, Kentucky- USA). The hexafluorophosphate 
(PF6) salt of 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono-N-
hydroxysuccinimide (DOTA-NHS) ester was purchased from Macrocyclics (Dallas, 
Texas/ USA). N-(biotinyloxy)succinimide (biontinyl-OSu) was purchased from 
BACHEM (Torrance, California/ USA). Dabsyl-L-valine (Dv acid) was purchased from 
TCI Inc. (Tokyo).  ( 3-(2-((3-Chloro-5trifluoromethyl)-2-pyridinyl)oxy)-anilino)-3-
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oxopropanionic acid (Ct acid) and 4-(4-(4chlorobenzyl)piperazino)-3-
nitrobenzenecarboxylic acid (Cb acid) ligands were procured from Bionet Research (Key 
Organics Ltd. – Camelford, Pennsylvania/ USA)). Acetonitrile (MeCN), dichloromethane 
(DCM), N,N-dimethylformamide (DMF), diisopropylethylamine (DIEA), hydrazine, 
trifluoroacetic acid (TFA), 1,3-diisoproylcarbodiimide (DIC), 1-hydroxybenzotriazole 
(HOBt), 20 % pyridine/DMF and triethylsilane (Et3SiH or TES) were purchased from 
Sigma-Aldrich (St. Louis, Missouri / USA).  
Instrumentation. Solid support syntheses were carried out in Pierce polyethylene 
columns (5 mL). All SHALs were purified by semi-preparative HPLC at 10 mL/min on a 
Waters preparative machine with photodiode array detection (Waters Symmetryprep C18, 
7 µm, 19 x 300 mm column) and lyophilized using Kinetics Flexi-Dry freeze-dryer. The 
purity was confirmed by analytical HPLC carried out at 1 mL/min on an Agilent 1100 
machine (Waters Symmetry C18, 5 µm, 4.2 x 150 mm column, diode array detector) with 
a linear gradient from 95 % H2O (1 % TFA) to 80 % MeCN (1 % TFA) over 12 min.  
Mass spectra were acquired on a Micromass Quattro Micro API mass spectrometer 
operating in positive ion mode. The samples were dissolved in MeCN / H2O (1:1), 0.1 % 
formic acid for mass spectrometry analysis.  
Preparation of Resin 1: 2-Chlorotrityl chloride resin (100 mg, 0.13 mmol) was 
suspended in 2 mL dichloromethane (DCM) for 30 min and washed 3x with anhydrous 
dimethylformamide (DMF). The resin was treated with Fmoc-D-Lys(Boc)-OH (20 mg, 
43 µmol, 468.5 g/mol, 0.33 equiv. of the resin, the limiting reactant) and DIEA (25 µL, 
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144 µmol) dissolved in 1.0 mL anhydrous DMF (Scheme 1). The reaction mixture was 
agitated on a nutator for 3 h. Ethanol (1.0 mL) and DIEA (100 µL) was added and agitated 
for 15 min to quench the excess chlorotrityl chlorides on the resin. The reaction solution 
was removed by filtration and the resin was washed 3x with DMF and treated with 20 % 
piperidine/DMF (1 mL) for 20 min for fluorenylmethoxycarbonyl (Fmoc) deprotection. 
The Fmoc-deprotected resin-bound Boc-lysine (Resin 1) was washed with DMF and 
subsequently coupled to the next Fmoc-protected residue using amide-coupling chemistry 
employing ~4-5 molar equivalents of DIC and HOBt in DMF. The washing and filtration 
cycle with DMF (2 mL, 3x, 1 min each) was performed between every deprotection and 
coupling steps. 
Preparation of Resin 2: Resin 1 was treated with a solution of Fmoc-8-amino-
3,6¬dioxactanonic acid (50 mg, 0.13 mmol, 385.4 g/mol, 3 equiv. of the limiting reactant), 
DIC (30 µL, 0.19 mmol, 126.20 g/mol, 0.815 g/mL), and HOBt (26 mg, 0.19 mmol, 
135.12 g/mol) in 1.0 mL anhydrous DMF for 3-5 h (coupling cycle 2, step 1a and 1b). 
The resin was then treated with Fmoc-D-Lys(Dde)¬OH, HOBt and DIC in 1.0 mL 
anhydrous DMF for 5 h (coupling cycle 3, step 2a and 2b). After Fmoc deprotection, the 
resultant free amine was subsequently coupled to another solution of Fmoc-8-amino-
3,6¬dioxactanonic acid (Fmoc-mini-PEG), HOBt and DIC in 1.0 mL anhydrous DMF for 
3-5 hours (coupling cycle 4, step 3a and 3b) producing Resin 2 after 20% piperidine/DMF 
Fmoc deprotection and washing the resin with DMF to remove the excess reagents. 
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Synthesis of SH7153. Resin 2 was treated with 93033 (32 mg, 0.085 mmol, 
375.81 g/mol, 1.5 equiv.), HOBt and DIC in 1.0 mL anhydrous DMF for 5-12 h (coupling 
cycle 8, step 1a). The reaction solution was filtered and the resin was washed and treated 
twice with 4 % hydrazine in DMF (40 µL Hydrazine in 900 µL DMF for 10 min) to 
remove the 1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl (Dde) protecting group (step 
1b). After washing, the resulting resin was treated with 689002 (30 mg, 0.080 mmol, 
374.71 g/mol), HOBt and DIC in 1.0 mL anhydrous DMF for 5-12 h (coupling cycle 9, 
step 2). In the last step, the solvent was exchanged from DMF to DCM (2 mL) and resin 
was washed with DCM. The washed resin was then treated with 2 mL of 20 % TFA / 1 % 
TES in DCM for 30 min to cleave the product from the resin as well as the Boc-protecting 
group on the ε-amine of the first lysine residue. The cleaved solution was filtered and the 
resin was washed with DCM. The combined DCM filtrate (red) was concentrated. The 
crude material was analyzed by analytical Agilent HPLC (to determine the ratio of product 
/ impurities in the cleaved material using UV absorbance peak areas at 254 nm). 
Purification was performed using semi-preparative HPLC and the product fractions were 
lyophilized to dryness. Analytical HPLC chromatograms and electron spray ionization 
mass spectroscopy (ESI-MS) was used to confirm the final product. 
2.5. Antibody neutralizing assays 
For antibody neutralization assay Raji cells were used, a human B cell line that 
expressed high amounts of CD81 on the surface (data not shown). Cells were grown in 
RPMI medium (10% FCS, 1% penicillin/streptomycin, 1% L-glutamine, 1% non-
essential amino acids, 1% sodium pyruvate, pH 7.4, at 37oC with 5% CO2). 2x10
5 cells 
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were incubated with or without different concentrations (50 µM, 100 µM, 400 µM and 1 
mM) of indicated inhibitor for 20 min at room temperature, subsequently 1 ul (16 ng/µl) 
of FITC-labeled anti CD81 antibody (BD Pharmingen, 551108) was added to the cells 
and incubated for 20 min (antibody titration was performed to obtain a working dilution 
range, data not shown). Cells were washed and analyzed by FACS (BD FACSCalibur, 
software: Cell Quest Pro). Mean Fluorescence Intensity MFI was calculated using Flowjo 
software (TreesStar, www.flowjo.com).    
2.6. HCV infection assays 
Pseudotyped retroviral particles harboring HCV envelope proteins (HCVpp) from 
different genotypes were produced as described previously [23, 24] with plasmids kindly 
provided by F.L. Cosset, J. Ball, and R. Bartenschlager. A plasmid encoding the feline 
endogenous virus RD114 glycoprotein [25] was used for the production of RD114pp. 
Both HCVpp and RD114pp expressed Firefly luciferase. 
The cell culture-produced HCV particles (HCVcc) used in this study were based 
on the JFH1 strain [26] and were prepared as described previously [27, 28]. They were 
engineered to express the A4 epitope, titer-enhancing mutations and Gaussia luciferase 
[27,28].  
To identify ligands that inhibit HCV infection, Huh-7 cells were seeded in 96-well 
plates and treated the day after with six different concentrations of each ligand diluted in 
DMSO in duplicate using a Zephyr automated liquid handling workstation (Caliper 
BioSciences, Hopkinton, MA). The final concentration of DMSO (1%) was adjusted to 
be the same for all ligand concentrations. Cells treated with DMSO were used as negative 
controls. Cells treated with different concentrations of anti-CD81 (JS-81 from BD 
Pharmingen, San Jose, CA) 1 hour before infection, were also used as positive controls. 
The third day, RD114pp, HCVpp or HCVcc were inoculated and incubated for 30 hours 
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at 37°C. Firefly and Gaussia luciferase assays were performed as indicated by the 
manufacturer (Promega, San Luis Obispo, CA).  
3. Results 
 Our previous analyses of two sets of small molecules predicted to bind to the large 
cleft on the open conformation of CD81-LEL and to an adjacent cavity nearby identified 
26 small molecules that bind to the large extracellular loop of CD81. These compounds 
are being evaluated as potential leads for modification or optimization (e.g. by fragment 
based drug design or the development of SHALs) to create steric inhibitors that block the 
binding of HCV E2 glycoprotein to CD81 on hepatocytes. Using dual polarization 
interferometry, one of these compounds (689002) was shown to block the recombinant 
E2 glycoprotein binding to CD81-LEL immobilized on a chip. Additional binding studies 
have been conducted in an effort to identify other ligands that might also block the HCV 
E2: CD81 interaction and be used in combination with 689002 to create a bidentate SHAL 
with improved CD81 binding. 
3.1. Identification of a Second Ligand that Blocks E2 binding to Recombinant 
CD81-LEL 
Dual polarization interferometry (DPI) experiments conducted with a set of small 
molecules that were predicted to bind to a second cavity on CD81-LEL (11) (adjacent to 
key CD81 amino acids (8,9) that contribute to CD81’s binding to the HCV E2 
glycoprotein) identified a second small molecule that blocks recombinant E2 binding to 
CD81-LEL. In these experiments, recombinant HCV E2 glycoprotein was immobilized 
on a chip and dual polarization interferometry (DPI) was used to compare the binding of 
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CD81-LEL, in the absence and presence of 500µM ligand, to the immobilized E2. As we 
reported previously (11), the compound 689002 (9-Oxo-9H-thioxanthene-3-carboxamide 
10,10-dioxide) was observed to block CD81 binding to E2 (Table 1). During the screening 
of the Site 2 ligands, a second compound, 93033 (4-(2-(2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-1-yl)acetamido)-2-hydroxybenzoic acid), was also found to block 
CD81-LEL binding to E2. In both cases, the DPI response in radians produced by CD81-
LEL binding to E2 was reduced dramatically when the CD81-LEL-ligand mix was added 
to the E2 immobilized on the chip. In contrast, ligand 30930 (5-(benzyloxy)-1H-indole-
2-carboxylic acid, which is shown as an example of a negative control) was observed to 
have no effect on CD81-LEL binding.  
3.2. Design and Synthesis of a Prototype Bidentate SHAL 
The lowest energy conformations of 689002 and 93033 bound to CD81-LEL, as 
identified by AutoDock (figure 1A), were used to design a first generation bidentate 
SHAL. As a first step, the distance from the amino nitrogen on 689002 and the carbon on 
93033’s carboxyl group was measured to define a minimum length that would be required 
for the linker connecting the two ligands. While the linear distance between these atoms 
was measured to be 8.15A (figure 1B), the linker was designed to be longer (~12A) to 
allow it to extend over the amino acid Glu188 (colored cyan) located between the two 
ligand binding sites. Using this length to define the distance of separation between the two 
ligands in the SHAL, a scaffold to which the two ligands would be conjugated was 
designed (figure 2). As is typical of all first generation SHALs, lysine and miniPEG 
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molecules were used to create the scaffold. Lysine residues were used at the terminus of 
the SHAL to provide a free amine and free carboxyl group to which various tags and 
effectors can be attached to the SHAL. Internal lysine residues were employed to provide 
branch points within the scaffold. MiniPEG molecules were incorporated to provide 
distance between linked ligands and also to make the linker flexible and contribute to 
overall SHAL solubility.   
Solid phase synthesis and carbodiimide coupling chemistry was used to connect 
the components to the resin and create the molecular scaffold of the SHAL, and ligands 
689002 and 93033 were subsequently conjugated to the appropriate sites on the scaffold 
(figure 3). Following cleavage from the resin and HPLC purification, 20 milligrams of 
SH7153 (molecular mass of 977.00 Da) were obtained. Two additional by-products of the 
reaction, SH7153A (8 mg, molecular mass of 960.04 Da) and SH7153B (7 mg, molecular 
mass of 993.97 Da) were also obtained (figure 4). SH7153A is a bidentate SHAL 
containing two 689002 ligands linked together. SH7153B is a bidentate SHAL containing 
two 93033 ligands linked together. 
3.3. Analysis of SH7153 Binding to CD81 
SH7153 was first tested using surface Plasmon resonance to determine if it would 
bind to recombinant CD81-LEL immobilized on a chip.  As shown in Figure 5A, SH7153 
not only bound to CD81-LEL, but it also dissociated slowly from the protein (koff ~ 2.17E-
04 1/sec). This is in marked contrast to the results obtained with the two ligands. Both 
689002 and 93033 also showed reasonable binding responses, but the two ligands 
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dissociate rapidly (figure 5B) as is characteristic of weakly bound small molecules. The 
off rate for 689002 was 0.002631 1/sec and the off rate for 93033 was 0.00239 1/sec. A 
series of binding curves were obtained for the SHAL and two ligands at different 
concentrations to obtain an estimate of their affinities for recombinant CD81-LEL. Both 
ligands bound weakly and had Kd’s that were greater than 200 µM (Table 2). SH7153, in 
contrast, bound with a Kd of 21 µM.  
The relative strength of binding of SH7153 and the two by-products of the SHAL 
synthesis SH7153A and SH7153B to native CD81 was then tested by measuring their 
ability to block the JS-81 antibody binding to Raji cells. It was shown that SH7153 and 
the 2 by-products didn’t give a significant inhibitory effect.  
4. Discussion and conclusions 
Virtual screens performed in an earlier study by docking a large library of diverse 
small molecules into two neighboring cavities on the open conformation of CD81-LEL 
led to the identification of two sets of compounds that were predicted to bind to CD81 
(11) in the same region where the HCV glycoprotein E2 has been reported to bind (8,9). 
Experimental testing of these compounds revealed that 26 of the molecules bound to a 
recombinant form of CD81 LEL. One of the molecules predicted to bind to the largest 
cavity, 9-O-9H-thioxanthene-3-carboxamide 10,10-dioxide (689002), was found to block 
E2 binding to recombinant CD81-LEL (11). Our recent testing of the other set of 
molecules predicted to bind to the smaller cavity on CD81-LEL led to the identification 
of a second compound that blocks E2 binding to CD81-LEL, 4-(2-(2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-1-yl)acetamido)-2-hydroxybenzoic acid  (ligand 93033).  
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Both ligands 689002 and 93033 were identified by docking experiments 
conducted using two cavities that are only present on the surface of the open conformation 
of CD81-LEL (11). Although molecular dynamics studies of the open conformation 
conducted by Neugebauer et al. (13) have been used to suggest that a second, closed 
conformation of CD81-LEL reported by Kidadokoro et al. (14) was more likely to be the 
physiologically relevant conformation, Neugebauer et al.’s (13) own analysis of the 
dynamics data suggested the two conformations might exist in dynamic equilibrium. This 
hypothesis has been supported by the small molecule binding studies we conducted using 
recombinant CD81-LEL. More than 72% of the ligands predicted by docking to bind to 
the large cleft/cavity present only in the open conformation of the protein were found by 
experiment to bind to CD81-LEL (11). 
The prediction that the two molecules bind to two adjacent cavities surrounding 5 
of the 7 key CD81 amino acids that bind to E2, and the docked conformations of the two 
molecules showing that both molecules contain carboxyl groups that do not appear to 
interact appreciably with CD81 (so it is available for conjugation to a linker) and are 
oriented toward each other all suggest 689002 and 93033 are good choices to link together 
to create a prototype bidentate SHAL that targets the E2 binding site on CD81. The docked 
conformations of the molecules bound to CD81-LEL were used to design a linker scaffold, 
and the first CD81 SHAL, SH7153, was then synthesized using solid phase chemistry. 
Upon purification by HPLC, SH7153 and two by-products (bidentate SHALs containing 
two of the same ligands) were obtained.  
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Surface Plasmon resonance analyses of SH7153 binding to CD81-LEL showed 
the SHAL bound to the recombinant protein with a Kd of ~21µM. Estimates obtained for 
the Kd’s of the two ligands used to create the SHAL (both 689002 and 93033 had Kd’s 
>200 µM) indicate the linking together of 689002 and 93033 resulted in the production 
of a SHAL with a Kd that is at least 10 fold higher than the Kd of the individual ligands. 
In addition, the SHAL was observed to dissociate from CD81-LEL slowly with an off-
rate that is similar to or slower than the HCV E2 protein (15) and a number of HCV 
neutralizing antibodies (16). Flow cytometry experiments were also conducted to examine 
SH7153 binding to native CD81 on Raji cells using the JS-81 antibody as a competitor. 
While an initial set of experiments suggested SH 7153 inhibited JS-81 binding to CD81 
on Raji cells in a dose dependent manner, recent experiments have not confirmed that 
inhibition. Subsequent HCV infection experiments also showed this first SHAL was not 
effective in inhibiting HCV viral infection of Huh-7 cells. 
While kinetic data obtained for a specific binding event that occurs between two 
isolated proteins can contribute a great deal to our understanding of that particular 
interaction, the results may not necessarily reflect what happens between the two proteins 
in their native state. In the case of inhibitors designed to prevent HCV E2 binding to CD81 
and block viral entry and cell infection, a number of factors can have a profound impact 
on how well the drug induces its effect. Recombinant protein interactions in solution, for 
example, may not be the same as the interactions that occur between E2 when it is 
associated with the virus and CD81 when it is located in the target cell’s membrane. E2 
is known to form a heterodimer with E1 in the membrane of HCV, and E2 in the dimer 
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may react differently when E2 is free in solution. Protein structural dynamics may also 
affect the number of available binding sites. The number of binding events required per 
cell to trigger viral entry and infection, the number of available CD81 molecules, and 
subtle structural variations in the HCV E2 protein expressed by different viral genotypes 
that may modulate the interaction of the protein with CD81 are also important. The impact 
of these factors may explain some of the variability in kinetic data others have obtained 
and may have led to major differences in opinion as to what the Kd of an antibody or 
inhibitor needs to be to effectively block HCV binding to CD81. Based on Kd’s 
determined for HCV E2 binding to CD81, Petracca et al (17) suggested antibodies would 
need to have nanomolar affinities to block HCV from binding to CD81. However, Keck 
et al (18) and Nakajima et al. (15) reported Kd’s for HCV E2 protein binding to CD81 
that were only in the micromolar range. The requirement for a Kd in the micromolar range 
was further supported by the mathematical modeling of HCV viral kinetics conducted by 
Padmanabhan and Dixit (19). The Kd for E2 binding to CD81 was estimated from their 
mathematical treatment of HCV infections to be in the range of 10-100 µM.  
The current results show that we can effectively combine rapid virtual screening 
of large libraries of compounds with the experimental testing of a small number of hits to 
identify lead small molecules that can be linked together to create a SHAL. By linking 
together the two weak binding ligands 689002 and 93033, we have been able to create a 
first generation bidentate SHAL that binds to CD81 with an affinity that is higher than the 
affinities of the individual ligands used to create it. While this first SHAL did not inhibit 
HCV infection of Huh-7 cells, the SHALs µM affinity and slow off-rate observed for the 
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SHAL binding to CD81-LEL is encouraging. Based on our previous experience with 
second generation SHALs developed for cancer therapy, improvements in binding affinity 
and efficacy can be accomplished through the optimization of linker lengths, replacing 
one ligand with another, or by adding a third ligand to create a tridentate SHAL.  
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Figures. Figure 1. The binding modes of ligands 689002 and 93033 to CD81-LEL. 
The docked conformations of ligands 689002 (pink) and 93033 (blue) are shown binding 
to Sites 1 (large cleft on right) and Site 2 (smaller cavity on left) located within the E2 
binding site on CD81-LEL (A). The linear distance between ligand carboxyl groups was 
measured to be 8.15A, but linker was designed to be longer (~12A) to allow it to bend 
over amino acid Glu188 (colored cyan) located between the two ligand binding sites (B). 
6.  
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Figure 2. The Linker Molecular Scaffold of SH7153. The molecular scaffold designed 
to link ligands 689002 and 93033 together to create SHAL SH7153 is comprised on lysine 
and miniPEG residues. The terminal lysine residue provide a free amine and carboxyl 
group that can be used to attached tags or other effectors. Lysine residues are also 
incorporated to provide branch points within the linker and miniPEG molecules are used 
to provide distance between ligands and help optimize the SHAL’s solubility. 
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Figure 3. Synthetic scheme used to synthesize SH7153. Solid phase synthesis was 
performed on a chlorotrityl resin. For a detailed description of the synthesis, please see 
the Experimental section 
 
  
. 
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Figure 4. Structures of the two SHAL by-products isolated from the SH7153 
preparation by HPLC. SH7153A was found to contain two 689002 ligands linked 
together.  SH7153B was found to contain two 93033 ligands linked together. 
 
 
 
 
 
 
 
 
  
SH7153A SH7153B 
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Figure 5A. Binding and dissociation curves for the SHAL SH7153 and its two ligand 
components binding to recombinant CD81-LEL obtained by surface Plasmon 
resonance. A detailed description of the experiment is described in the Experimental 
section. A. Binding and dissociation of SH7153. B. Binding and dissociation of the ligand 
component 93033. 
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7. Tables 
Table 1. DPI data for ligands 689002 and 93033. Ligands 93033 and 689002 were found 
to interfere with HCV E2 binding to CD81.Ligand 30930 was used as a negative control. 
 
Added to E2 on Chip DPI Response in Radians (Rad) 
CD81-LEL 2.52 
30930 2.52 
93033 0.25 
689002 -0.23 
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Table 2. The kinetics study of SH7153, ligands 689002 and 93033. 
Ligand or SHAL Kd (µM) Off rate (1/sec) 
93033 >200 0.00239 
689002 >200 0.002631 
SH7153 21 2.17E-04 
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CHAPTER V 
 281816- A NOVEL DRUG LEAD IDENTIFIED TO INHIBIT HCV INFECTION 
IN A GENOTYPE-INDEPENDENT MANNER 
This chapter is based on a paper titled “Identification of a novel drug lead that inhibits 
HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.” that 
was submitted to Plos one by: Reem R. Al Olaby, Laurence Coquerel, Adam Zemla, Jean 
Dubuisson, Laure Saas, Jost Vielmetter , Joseph Marcotrigiano, Abdul Ghafoor Khan, 
Felipe Vences Catalan, Alexander L. Perryman, Joel S. Freundlich, Stefano Forli, 
Shoshana Levy, Rod Balhorn , Hassan M.E. Azzazy.  
Objectives 
The aims of this study is to create a new homology model of HCV E2 based on 
the newly resolved crystal structures (PDB IDs: 4MWF, 4NX3), screen ~2000 ligands 
against the HCV E2 homology model and identifying top virtual screening hits, test the 
hits using lab on a chip techniques and antibody neutralizing assays, test the ligands with 
the best binding affinity using HCV infection inhibition assays and do further tests for the 
drug lead 281816 to determine its effect on cell to cell transmission of HCV and other 
aspects. The Homology model was created by Dr. Adam Zemla (Lawrence Livermore 
National Laboratory – USA), the virtual screening runs were conducted in Scripps 
Research Institute (USA), Dr. Arthur Olson’s molecular graphics laboratory and Rutgers 
University (USA) at Dr. Joel Freundlich’s lab. The HCV infection inhibition assays were 
done in Institute Pasteur De Lille (France) at Dr. Jean Dubuisson’s lab and the antibody 
neutralizing assays were done in Stanford University (USA) at Dr. Shoshana Levy’s lab.  
1. Introduction 
Hepatitis C Virus (HCV) is a global public health problem [1] in which nearly 
85% of affected individuals have acute HCV infections and exhibit no symptoms. In 
addition, more than three-quarters of these cases will advance to chronic disease, which 
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include liver cirrhosis and liver cancer [2]. The current standard of care treatment for HCV 
(Peginterferon/Ribavirin, PR) can cause deleterious side effects, and a sustained virologic 
response (SVR) is achieved in less than 50% of genotype-1 patients [3]. The FDA 
approved protease inhibitors Telaprevir (TVR) and Boceprevir (BOC) have been shown 
to provide higher SVR rates in genotype 1 patients [3, 4] when each is combined with PR. 
However the poor safety profile of TVR and BOC reported in the Week 16 analysis of the 
French Early Access Program suggest there is still a need for better HCV drugs [5]. The 
two most recent FDA approvals have been for the oral drugs Simeprevir and Sofosbuvir, 
inhibitors that target the HCV NS3/4A protease and polymerase, respectively [6]. 
Semiprevir, which needs to be administered with ribavirin and peg-interferon, has a 
number of undesirable side effects [7]. The efficacy of Semiprevir has also been shown 
to be diminished significantly due to viral breakthrough (HCV RNA rebounds and 
becomes detectable in the patient before treatment is completed), in patients infected by 
HCV genotypes 4-6 containing the Q80K, R155K and D168E/V polymorphisms [7]. 
Recommendations for the use of Sofosbuvir indicate it should be administered with 
Ribavirin to HCV genotype 2 and 3 infections and that Peg-Interferon should be included 
in the treatment when infections involve genotypes 1 and 4. While Sofosbuvir is 
considered the Holy Grail in HCV treatment by some, it is recommended that treatments 
be limited to 12 weeks [6]. Its high cost ($1,000 USD/pill) also puts it out of reach of 
many HCV infected patients. This has led many of the larger pharmaceutical companies 
to continue developing new drugs that target one or more steps in the HCV life cycle and 
block virus invasion, processing of the pro-protein or replication of the viral genome.  
Several research groups have shown that the CD81-large extracellular loop 
(CD81-LEL) plays a key role in HCV entry into cells by binding to the HCV envelope 
glycoprotein 2 (E2) [8-11]. Zhang et al. [12] elucidated a separate, additional function for 
CD81 in the HCV life cycle. These studies revealed that CD81-LEL is important for 
efficient HCV genome replication. In addition, the E2-CD81-LEL interaction has been 
determined to induce several immuno-modulatory effects such as the production and 
release of pro-inflammatory cytokine gamma interferon from T-cells. In addition, this 
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interaction has also been shown to down regulate T-cell receptors and suppress the activity 
of natural killer (NK) cells [13]. Therefore, it is tempting to speculate that blocking the 
CD81- LEL:HCV E2 interaction might also contribute to arresting disease progression to 
liver cirrhosis.  
Following the discovery of the E2 glycoprotein’s role in HCV infection and 
disease progression, several approaches have been used to attempt to develop anti-HCV 
drugs and vaccines that target the HCV E2 glycoprotein [14-17]. These efforts have had 
to deal with challenges that relate to the genomic diversity and heterogeneity of HCV, 
limitations in animal models used to test vaccines and drugs, and the lack of a resolved 
crystal structure for the HCV E2 glycoprotein. Recently, two crystal structures have been 
reported for the core ectodomain of the HCV E2 protein [18, 19]. Kong et al. [18] obtained 
the structure of amino acid residues 384-746 (E2c) by designing and expressing 41 soluble 
HCV E2 constructs and selecting 15 to screen against E2-specific Fab fragments in 
crystallization trials. Using a combination of x-ray crystallography and negative stain-
electron microscopy, Kong et al. [18] showed that the structures they obtained for E2 were 
globular and very different from the predicted models of E2 that were developed using 
class II fusion protein templates containing three β-sheet domains. Additionally, they were 
able to identify key CD81-binding residues through mutational studies. Important CD81 
binding sites were determined to be in the epitope recognized by the neutralizing antibody 
AR3C, along one s -sandwich (an isolated region of the CD81-binding loop) 
and a front layer consisting of loops, short helices and β-sheets [18-20]. AR3C was also 
found to cross-neutralize HCV genotypes by blocking CD81 binding to HCV E2 [21]. 
During the preparation of this manuscript, a second structure was reported for E2c (amino 
acid residues 492-649) by Khan et al. [19]. This new structure, which was obtained by 
crystallizing E2c in complex with a FAB fragment of the mouse monoclonal antibody 
2A12, is highly similar to the previously reported structure. In addition to providing a 
second structure for the E2 core from a different HCV genotype (2a), new information 
was also reported on the accessibility of the E2 core amino acids within the structure using 
a combination of limited proteolytic degradation and deuterium exchange. 
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Despite the advances in the field of HCV drug development, the current drugs 
offer little protection against the emergence of genetic variants (escape variants) of HCV 
– a feature of HCV biology that complicates both drug and vaccine development. Drugs 
that target only one step in the HCV life cycle may be less effective in treating patients 
who become infected with these emerging variants. In an effort to develop a suitable drug 
candidate that targets the majority of the existing HCV genotypes, we developed an HCV 
E2 homology model based on the new HCV E2 core crystal structure reported by Kong 
et al. [18] and have used this model to identify small molecule drug leads that target highly 
conserved sites on the HCV E2 glycoprotein located within the region bound by CD81. 
AutoDock was used to perform virtual screening runs against 1715 small molecules and 
34 of the best compounds were tested experimentally using surface Plasmon resonance 
(Biacore T100) to identify a set of small molecules that bind to the recombinant E2 
protein. The compounds showing binding activity were then tested for their ability to 
block HCV infection of Huh-7 cells. One compound, 281816, was found to block 
infection of the cells by each of the HCV genotypes and subtypes tested (1a, 1b, 2a, 2b, 
4a and 6a) in a dose-dependent manner. Experiments with Huh-7 cells have shown that 
both mechanisms that lead to HCV infection, cell-free and cell-to-cell transmission, are 
abrogated by 281816. Inhibition of cell-free infection is limited to the viral attachment 
step, as well as interactions occurring during viral internalization and fusion; 281816 
appears to have no effect on post-entry processes. 
2. Results  
a. Structural model of E2 
In order to maximize the likelihood that these experiments would lead to the 
discovery of small molecules that bind to E2 and block E2’s binding to CD81, we 
developed a homology model of the core of the E2 protein containing the domains known 
to bind to CD81 to use as our docking target. This model was created using the HCV 
genotype 1a protein sequence NP_751921.1 and the crystal structure of E2c as the primary 
template (PDB entry: 4MWF) (18). Using a model, rather than the E2c crystal structure, 
was important because the reported structure of E2c was determined to be unsuitable for 
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the docking experiments we needed to perform. The atom coordinates listed in PDB 
chains 4mwf_C and 4mwf_D provide structural information for only 169 and 171 residues 
respectively out of the 363 amino acids present in the full-length E2 protein. Within each 
of deposited PDB chains three stretches of amino acid sequence (large loop P453-P491 
containing 39 amino acids, T542-G547 or V574-N577, and F586-R596) are missing in 
the crystal structure (figure 1A). Unfortunately, similar regions are also missing in the 
crystal structure of the genotype 2a HCV E2c protein (PDB chain: 4nx3_D) reported by 
Khan et al. [19] which provides atom coordinates for only 119 amino acids. Structural 
superposition of 4mwf_C and 4nx3_D (figure 1B) shows strong conformational 
similarities between the experimentally solved structures of the E2 proteins with a root 
mean square deviation of 1.07 Ångstroms measured on 98 residues for which distances 
between corresponding Cα atoms are under 3 Ångstroms. The most significant structural 
deviations are observed in the region 566-601 (numbering from 4mwf_C) which 
corresponds to the region that also exhibits the greatest variation in sequence (see 
sequence alignment in Figure 1A).  
Exhaustive structure similarity searches of 90 residue structural fragments of E2 
conducted using the entire PDB database (255,302 PDB chains) revealed that no 
additional structural homologs could be found at the level of calculated structure 
similarities by LGA score [22] higher than LGA_S=45%, suggesting that the HCV E2 
protein represents a novel fold in the current PDB. Thus, the modeling of the structure of 
the insertions needed to fill in missing regions in the experimentally solved crystal 
structure and to complete the model was a difficult task, and it was completed with a very 
low degree of confidence. By applying a combination of structural modeling and analysis 
methods to the E2 crystal structure (see Materials and Methods section), we were able to 
construct a model that met all the requirements needed for docking. This model contains 
the peptide segments and loops that are missing in the E2c structure (figure 2), the missing 
fragment with amino acids known to be critical for E2 binding (W487), as well as the 
exact sequence for the HCV genotype 1a E2 protein. Three regions that have been 
identified by others to be critical for E2 binding to CD81 [24-26] are contained in the 
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model in their entirety (figure 2). Currently, however, only three of the twenty-one Region 
1 amino acids (H421-N423) are present in the model. A comparison of our model to the 
two E2c structures (see bar plots in the Figure 1A and superposition of two structures in 
Figure 2) shows the main core regions are, as one would expect, very similar. The 
differences that are observed in the core region are small and appear to reflect only minor 
local deviations between experimentally solved structural templates. The large region that 
does differ corresponds to the missing peptide segments (Figure 4). 
b. Ligands predicted to bind to CD81 binding sites on E2 
Five ligand-binding sites on the HCV E2 homology model (Figure 3) were 
identified by docking of the National Cancer Institute’s Diversity Set III library of ligands 
to the E2 model. Each of these sites is associated with or positioned next to one or more 
of the amino acid or peptide sequences that have been identified by others to either 
participate in E2 binding to CD81, E2 binding to E1 or to be important for HCV 
infectivity. The first sequence of importance is the peptide segment Q412-N423 that was 
identified to bind to the broadly neutralizing antibody AP33 [20, 27]. Alanine mutagenesis 
studies have shown all of the amino acids in this region appear to be important for HCV 
infectivity [24]. The model used in this study currently contains only three of the amino 
acids that correspond to this segment, H421, I422 and N423. Sequence 2 spans the second 
hyper-variable domain of E2, extending from amino acid Y474 to R492 [13, 24-26]. The 
majority of amino acids in this sequence have been shown to have no effect on E2 binding 
to CD81 when mutated [23], but antibodies binding to this region of the protein do inhibit 
HCV infectivity [25] and CD81 binding [27]. One amino acid located within this domain, 
W487, does however appear to be critical for E2 binding to E1. This amino acid is the 
first residue in one of the WHY motifs that have been reported to play a role in E1:E2 
dimerization [26]. The third sequence spans amino acids S522–G551 [20,24-26] and the 
fourth sequence of importance is comprised of amino acids P612–P619 [25]. Mutations 
of residues Y527, W529, D535, Y613, R614, W616, H617 and Y618 in these two regions 
have all been shown to eliminate E2 binding to CD81 [23,25]. Mutating all but three of 
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these amino acids (D535, R614 and W616) appears to eliminate specific interactions with 
CD81. W616 is the first amino acid in another WHY motif that is located in a region 
(G600-C620) that has been shown to be involved in fusion [28]. Alanine mutagenesis of 
D535, R614 and W616 was found to disrupt the structure of the AR3A epitope and 
indirectly impact CD81 binding [25].  
These five binding sites were used to guide to our selection of the top virtual 
screening hits to be tested experimentally for binding to recombinant E2 protein. While 
there is still some debate regarding the importance of the entire domains bound by 
neutralizing antibodies, amino acid mutagenesis studies have provided a great deal of 
insight into those amino acids located within the epitopes that participate in E2 binding to 
CD81. Based on this information, we have used the set of amino acids W420-I422, S424, 
G523, Y527, W529, G530, D535, P612-R614 and W616-P619, whose mutation has been 
shown to eliminate E2 binding to CD81, to identify locations within these sites (figure 3) 
where ligand binding would be expected to disrupt E2’s ability to bind to CD81.  
Thirty-four of the highest scoring ligands were selected from the docking run for 
experimental analysis. Conformers of each of the ligands bound to one or more of these 
five binding sites. The best ligands were considered to be those that exhibited the lowest 
free energy of binding and were predicted to interact with or bind nearby one or more of 
the E2 amino acids within the sites that were reported to be critical for E2 binding to 
CD81. The free energy of binding predicted for the best bound ligand conformations, 
shown in Table 1, ranged from -6.2 to -8.7 Kcal/mol. Additional criteria used to select 
among the group of ligands predicted to bind include the number of contact 
points/interactions (such as hydrogen bonds, salt bridges, Van Der Waals interactions) 
with amino acids in the model (the larger number of contacts or interactions the better) 
and the chemical structure of the ligands (preference is given to those that contain a free 
amino or carboxyl group that is exposed to solvent). Ligands with free amino or carboxyl 
groups can easily be linked to other ligands to create higher affinity or more selective 
second-generation inhibitors.  
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c. Experimental confirmation of ligand binding to HCV E2 
Each of the 34 ligands was tested experimentally using surface Plasmon resonance 
detection (on a Biacore T100 instrument) to determine if it would bind to recombinant 
HCV E2 protein and to obtain an assessment (relative to the other ligands) of how well it 
binds. Twenty-three of the molecules provided a positive change in response units (RU) 
indicating they bound to the E2 protein immobilized on the chip (Table 2). The measured 
responses for the ligands that bound varied from 54 to 276 RUs. Data was also obtained 
on the rate of ligand dissociation by measuring the amount of ligand remaining bound at 
two time points, dissociation 1 (10 seconds) and dissociation 2 (50 seconds), during the 
rinsing of the chip with buffer (figure 5). The majority of the ligands dissociated quickly, 
as one might expect for small molecules that bind to the surface of a protein. A few, such 
as ligands 121861, 4429, 158413, 81462, and 57103, exhibited slower off rates when 
compared to others.  
d. Inhibition of HCV Entry 
The 23 compounds that were observed to bind to recombinant E2 protein were 
then tested to determine if they would block HCV infection of Huh-7 cells. Pseudotyped 
retroviral particles harboring the envelope protein of an endogenous feline retrovirus 
(RD114pp) were first used to determine the specificity and the safety of molecules. We 
excluded from a further characterization the molecules for which the half maximal 
inhibitory concentration (IC50) against RD114pp was higher than 10 µM or the molecules 
that significantly increased RD114pp infection due to exerting non-specific inhibition 
(Table 3). The remaining ligands were next tested against pseudotyped retroviral particles 
harboring genotype-2a HCV envelope proteins (HCVpp 2a), cell culture produced HCV 
particles (HCVcc) or RD114pp. As a positive control, an anti-CD81 antibody was 
included in the assays. One compound, 281816, showed an inhibitory effect on both 
HCVpp and HCVcc infection with IC50’s of 1.02 µM and 3.95 µM, respectively (Table 
3 and Figure 6A), indicating that this molecule inhibits the entry step of the HCV lifecycle, 
probably through a specific effect on the virus’s interaction with CD81. While Huh-7 cell 
111 
 
toxicity was not observed over the range of ligand 281816 concentrations tested in the 
assays (the highest concentration tested was 10µM), a subsequent viability assay (MTS 
assay) showed a 50% cytotoxic concentration (CC50) for 281816 of 14 µM (data not 
shown). MTS is a tetrazolium compound that can be reduced by viable cells to generate 
formazan products that are directly soluble in cell culture medium.  
To determine if 281816 would inhibit HCV genotypes other than 2a, a series of 
infection assays was performed with HCVpp bearing envelope proteins from a number of 
different HCV genotypes. Interestingly, 281816 was found to be equally effective in 
inhibiting Huh-7 infection by all the HCV genotypes tested (1a, 1b, 2a, 2b, 4a and 6a, 
Figure 6B). The IC50 values ranged from 2.2 µM to 4.6 µM (Table 4). 
To confirm that 281816 inhibits HCV entry with no further effect on post-entry 
steps, 281816 (10 µM) was added at different time points (figure 8A) before (-2 to 0 hr, 
b), during (0 to 2hr, c), or after (2 to 24hr, d) inoculation of Huh-7 cells with HCVcc, as 
previously described [29]. Cells treated with dimethylsulfoxide (DMSO) and cells treated 
continuously (-2 to 24hr, a) with 281816 were used as controls. The results clearly showed 
that 281816 significantly inhibits HCVcc infection when present during virus infection 
(figure 8A, c). The decrease in HCVcc infection that was observed in condition b is likely 
to be due to some 281816 entering into the cells and acting on the entry step (figure 8A, 
b). Similarly, a slight decrease was also observed in condition d (figure 8A), which is 
likely related to 281816 acting on the entry of the remaining particles (those entering after 
2 hr). Together, these results confirm that 281816 inhibits the entry step of HCV lifecycle.  
After attachment to the cell surface and binding to entry factors, HCV virions are 
internalized by clathrin-mediated endocytosis [30, 31]. Following internalization, HCV is 
transported to early endosomes along actin stress fibers, where fusion seems to take place 
[31, 32]. To determine at which step HCV entry is impaired by 281816, we administered 
the ligand at different intervals during the early phase of infection. Virus attachment and 
binding were performed at 4°C (figure 8B, Steps 1 and 2). Then, cells were shifted to 
37°C to allow endocytosis and fusion (figure 8B, Step 3). Cells treated with JS81 were 
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used as controls where JS81 antibody binds to CD81 and blocks HCV E2: CD81 
interaction (data not shown). The addition of 281816 during step 2 and step 3 led to the 
strongest inhibition of HCV infection, as strong as the one observed when 281816 was 
present during all three steps. We also observed a significant inhibition of HCV infection 
when 281816 was added during the early attachment/binding steps (figure 8B, Step 1). 
Together, these results indicate that 281816 inhibits HCV infection by acting on more 
than the first (attachment/binding) step of viral entry. These data suggest the ligand also 
affects interactions during HCV internalization and fusion.   
e. Blocking of E2 binding to CD81 
Ligand 281816 was originally selected for testing based on the prediction by 
docking that it would bind to a site on the HCV E2 protein where CD81 binds. The 
infection assay conducted with Huh-7 cells demonstrated 281816 was effective in 
inhibiting the entry step in the HCV life cycle. To confirm that the binding of 281816 to 
E2 inhibits the HCV E2-CD81 interaction, flow cytometry was used to monitor the 
binding of a recombinant form of the E2 protein to native CD81 overexpressed on Raji 
cells as a function of 281816 concentration. The results in Figure 7 show binding of the 
E2 protein to Raji cells is inhibited by 281816 in a dose dependent manner.  
f. 281816 abrogates HCV cell-to-cell transmission  
In addition to cell-free infection, HCV can also be transmitted via cell-to-cell 
contact by a mechanism that is not completely understood [33, 34, 35]. Indeed, HCV is 
transmitted in the presence of monoclonal antibodies (mAbs) or patient-derived 
antibodies that are able to neutralize virus-free infectivity [33,35]. Since cell-to-cell 
transmission has been suggested to be a major route of transmission for HCV [34], we 
next analyzed the effect of 281816 on this process. For this purpose, Huh-7 cells were 
infected with HCVcc for 2h and then cultured with neutralizing anti-E2 antibody (3/11) 
in the presence of 281816 (1 µM and 10 µM). Cells cultured in presence of solvent 
(DMSO) and Epigallocatechin-3-gallate (EGCG, 50 µM) [35] were used as negative and 
positive controls of inhibition, respectively. Three days post-infection, foci were 
113 
 
visualized by immunofluorescence (figure 9) and sizes of foci were measured by counting 
the number of cells per focus. The results showed that 281816 led to a significant 
reduction of the number of cells per focus in a dose-dependent manner. Together, these 
results indicate that 281816 also inhibits cell-to-cell transmission of HCV. 
3. Discussion 
While it has been known for some time that the E2 envelope glycoprotein plays 
an important role in the life cycle of HCV, we are only now beginning to learn details 
about the structure of the protein and how it functions. This has been attributed to the 
challenging intrinsic properties of the protein, such as the presence of multiple flexible 
loops, its tendency to form disulfide aggregates in solution and the high level of N-linked 
glycosylation, all of which make it difficult to determine the protein’s structure. 
Neutralizing antibody epitope analyses and mutation studies, however, have provided a 
great deal of information about the regions of the E2 protein and specific amino acids that 
participate in CD81 binding and are important for HCV infectivity.  
It became possible to use computational docking and structure-based drug design 
methods to begin developing anti-HCV drugs that target the conserved regions of E2 and 
block its interaction with host receptors due to two reasons. First, the recent determination 
of two HCV E2 protein core crystal structures [18,19]. Second, our use of the deposited 
coordinates to create a new homology model of the protein’s structure containing the 
majority of conserved segments known to be important for viral invasion of hepatocytes. 
Our docking of a library of diverse small molecules to this homology model led to the 
identification of a set of ligands that were predicted to bind to sites near key amino acids 
known to participate in CD81 or E1 binding or block HCV infection, and 23 of the 34 
compounds were confirmed by experiment to bind to recombinant E2 protein. 
When these 23 ligands were tested for activity in blocking HCV infection of Huh-
7 cells, only ligand 281816 was found to inhibit HCV infection using both HCVcc and 
HCVpp based assays. Upon analyzing the activity spectrum of HCV using HCVpp 
bearing envelope proteins from different HCV genotypes (1a, 1b, 2a, 2b, 4a and 6a), 
114 
 
281816 was found to inhibit the infection of all tested genotypes with IC50’s ranging from 
2.2 µM to 4.6 µM (Table 4), indicating that this small molecule inhibits HCV entry in a 
genotype-independent manner. Ligand 281816 was also observed to block the binding of 
recombinant E2 protein to Raji cells expressing CD81. 
The docking experiments conducted with 281816 identified the two different 
binding sites on E2 shown in Figure 10. One cluster of 281816 conformers bound deep 
inside a cavity positioned directly above Y618 and P619, two amino acids in site 4 that 
are known to contribute to E2’s binding to CD81 [26]. The two strongest 281816 ligand 
binding modes are shown bound to this site. 281816 was also predicted to bind to a 
shallow cavity on the side of the protein. These conformers were predicted to bind to site 
1 near residues V515, G517, P515 and H421-N423. H421-N423 is part of a larger segment 
of E2 that has been shown to bind to CD81 [19]. As expected, the ligand positioned above 
Y618 and P619 in the deeper cavity was predicted to bind more strongly to the protein 
(free energy of binding of the best bound ligand = -8.64 Kcal/mol) than when it was bound 
to the shallow cavity on the side of the protein (free energy of binding = -6.39 Kcal/mol).  
A subset of the 281816 conformers (not shown) in the cluster observed to bind 
near site 4 overlapped into site 2 and bound immediately adjacent to D481-P490, part of 
the epitope targeted by antibodies that block HCV infectivity and E2 binding to CD81 
[27]. W487, a residue within this peptide segment whose mutation has been shown to 
disrupt E2:E1 dimerization [22], is also located near site 2. Other conformers in the cluster 
binding on the side of the protein also bound near site 5 and amino acid residues P612 and 
Y613. One interesting and unique feature of the 281816 ligand is that a number of its 
conformers are predicted to bind immediately above or next to the exposed faces of the 
P612-P619 domain that is known to participate in E2 binding to CD81 [26].  The limited 
proteolysis and deuterium exchange experiments conducted with the E2 protein core and 
reported by Khan et al. [19] indicate these 281816 binding sites are accessible and exposed 
to solvent.   
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To probe more deeply into the inhibition of the infection process by 281816, 
experiments were also run to determine if the inhibition of cell-free infection by 281816 
might be limited to viral entry, which step in the entry process might be affected by the 
compound, and what impact, if any, 281816 might have on cell-to-cell transmission of 
HCV. Analyses of Huh-7 cells inoculated with HCVcc before, during or after treatment 
with 281816 revealed the compound only blocks HCV entry and does not inhibit post-
entry processes in the HCV life cycle. A kinetic analysis of the effect of 281816, coupled 
with a temperature block to endocytosis and fusion, was used to examine the cell-free 
entry steps in more detail and showed 281816 inhibits not only the initial 
attachment/binding step, but it also has an effect on interactions that occur later during 
viral internalization and fusion. Ligand 281816 was also observed to abrogate the cell-to-
cell transmission of HCV. 281816 treatment of Huh-7 cells cultured in the presence of the 
anti-E2 neutralizing antibody 3/11 not only led to a dose dependent reduction in the 
number of cells forming foci, but it was found to be more effective in blocking cell-to-
cell transmission that the Epigallocatechin-3-gallate [35] used as a positive control.  
In addition to identifying a promising new small molecule drug lead for treating 
HCV that targets the E2 glycoprotein, this study also provides a demonstration of the 
utility of our new E2 homology model in the discovery of small molecules that bind to 
important sites on E2. By targeting sites containing amino acid residues identified by 
others to participate in CD81 binding and CD81-dependent processes that impact HCV 
infectivity, a small molecule was identified that not only blocks E2 binding to CD81 and 
the cell-free entry process, but it is also effective in blocking the cell-to-cell transmission 
of HCV – the predominant mechanism of transmission that contributes to the persistence 
of infections [34]. This effect of 281816 corroborates other reports of a CD81-dependent 
cell-to-cell transmission process [61.61] that can be blocked by anti-CD81 antibodies 
[34,66] and soluble CD81 [32].  281816, known as methiothepin or 1-methyl-4-(3-
methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazine, is also interesting 
because it has been determined previously to block dopamine [36] and serotonin [37] 
receptors and has been shown to inhibit a number of other biological activities, which 
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include the binding or entry of two other unrelated viruses into cells (Lassa [38], Marburg 
[39]), Plasmodium falciparum proliferation [40], and Mycoplasmodium tuberculosis 
infections [41]. 
4. Materials and Methods 
a. Creation of the homology model of E2 used for docking  
A crystal structure of E2c deposited in the PDB under a code 4MWF was resolved 
by Kong et al. [18] at a resolution of 2.65 Angstroms. However, upon examination of the 
structure file prior to docking, the set of reported atom coordinates of the protein was 
found to be incomplete. In addition to the coordinate file containing structural information 
for only 171 residues out of the 363 amino acids present in the full-length protein, 
structural information was missing for several peptide segments or loops within the 
structural core of the protein. In order to prepare a more complete version of the structure 
for docking, we have performed several homology modeling and structure analysis tasks 
using the coordinates of E2c as a template. The final structural model was created using 
the AS2TS system [42] based on atom coordinates from the PDB chains 4mwf_C and 
4mwf_D.  A structural search for similar fragments in proteins in the PDB that could be 
used to model missing loop regions was performed using the StralSV algorithm [43], 
which identifies protein structures that exhibit structural similarities despite low primary 
amino acid sequence similarity. The side-chain prediction was accomplished using 
SCWRL [44] when residue-residue correspondences did not match.  Residues that were 
identical in the template and E2 protein were copied from the template onto the model. 
Potential steric clashes were identified in the unrefined model using a contact-dot 
algorithm in the MolProbity software package [45], and the constructed model was 
finished with relaxation using UCSF Chimera [46]. 
b. Virtual screen of the NCI Diversity Set III to the HCV E2 protein model 
AutoDock VINA 1.1.2 (VINA) [47] was used to perform a virtual screen of the 
NCI Diversity Set III against the homology model that was created using the new crystal 
structure developed by Kong et al. [18] (PDB ID: 4MWF) as a template.  The model of 
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the protein was prepared for docking using the MolProbity Server (to add all of the 
hydrogen atoms and to flip the HIS/ASN/GLN residues if doing so significantly lowered 
the energy) and AutoDockTools 4.2 (which added the Gasteiger-Marsili charges and 
merged the non-polar hydrogens onto their respective heavy atoms) [48,49]. The NCI 
Diversity Set III library containing 1,715 models of compounds was obtained from the 
ZINC server (http://zinc.docking.org) [50].  The multi-molecule “mol2” files from ZINC 
were prepared for docking calculations using Raccoon [51], which added the Gasteiger-
Marsili charges, merged the non-polar hydrogen atoms onto their respective heavy atoms, 
and determined which bonds should be allowed to freely rotate during the calculations, to 
generate the “pdbqt” docking input format. 
Four different, overlapping grid boxes were used in this virtual screen to enable 
the docking calculations to explore almost the entire surface of this E2 model (except for 
the large, flexible loop that was added to the model and the relatively flat surface near 
it).  Since large grid boxes were used in these calculations, the “exhaustiveness” setting 
in VINA was increased to 20.  Each calculation used 8 CPUs on the Linux cluster at 
Rutgers University-NJMS.  The first box, which included P490, was centered at 38.829, 
12.968, -40.958 (x, y, z) and had the following dimensions:  24.0 x 35.0 x 30.0 (x, y, z in 
Angstroms).  The second grid box, which included G436, was centered at 48.401, 11.791, 
-14.449 (x, y, z) and had a size of:  32.0 x 36.0 x 24.0 (x, y, z in Angstroms).  The third 
grid box, which included S528, was centered at 51.644, 25.877, -27.795 (x, y, z) and 
encompassed 30.0 x 30.0 x 30.0 Angstroms.  The fourth grid box, which was selected to 
include the side of E2 not covered by the previous three grid boxes, was centered at 
57.777, 12.968, -34.067 (x, y, z) and enclosed 24.0 x 35.0 x 32.0 Angstroms (x, y, z). 
The docking outputs generated by VINA were processed and filtered using python 
scripts from Raccoon2 and Fox [51]. The top-ranked VINA mode from each docking 
calculation was harvested, and 17 different sets of energetic and interaction-based filters 
were investigated to harvest the most promising docking results for visual 
inspection.  The following parameters were explored in the filtering process:  -e indicates 
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the minimum estimated Free Energy of Binding from the VINA score in kcal/mol, -l is 
the minimum ligand efficiency value in kcal/mol/heavy atom, -S is the minimum number 
of hydrogen bonds between the ligand and target, and -H indicates that the ligand had to 
form a hydrogen bond with either a backbone amino group (::N) or a backbone carbonyl 
oxygen (::O) of any residue in that grid box.  
For the results with grid box 1, filters 12 and 13 each harvested 70 and 51 
compounds, respectively.  Those filtered sets were pooled together to form a set of 96 
unique compounds for visual inspection.  Filters 14 (which harvested 11 compounds), 15 
(which harvested 21 compounds), and 1 (which harvested 34 compounds) were pooled 
together from the results with grid box 2, in order to identify 52 compounds for visual 
inspection.  Similarly, for the results with grid box 3, filters 1 (which harvested 25 
compounds), 14 (which identified 20 candidates), and 15 (which harvested 13 
compounds) were pooled to obtain 34 compounds for visual inspection.  To identify 
candidates in the results with grid box 4, filters 1 (which harvested 26 compounds), 14 
(which harvested 19 compounds), and 15 (which harvested 14 compounds) were pooled 
to obtain 42 compounds.  These four different pools of potentially promising compounds 
were then visually inspected to select the ligands to be tested experimentally for binding 
to recombinant E2 protein. 
c. Expression and purification of the HCV E2 protein Con1eE2 
A construct containing a sequence encoding amino acids 384-656 of the Con1 
envelope protein 2 ectodomain (eE2) [19], a genotype 1 E2 sequence, was cloned into a 
lentiviral expression vector containing a carboxy-terminal Protein A tag separated by a 
PreScission Protease cleavage consensus sequence. eE2-ProtA was stably expressed in 
HEK293T cells using lentiviral infection. The protein was secreted into the media and 
supernatants were purified using IgG Sepharose (GE Healthcare, Piscataway, NJ). eE2-
ProtA was eluted with 100 mM sodium citrate and 20 mM KCl at pH 3 directly into tubes 
containing 1M Tris pH 9 for immediate neutralization. PreScission Protease (GE 
Healthcare, Piscataway, NJ) was added to the eluted sample at a ratio of 1:50 
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(enzyme:eE2), and the digest was then dialyzed into 20 mM HEPES pH 7.5, 250 mM 
NaCl, 5% glycerol. eE2 was separated from the cleaved tag and the PreScission Protease 
by ion exchange chromatography [19]. 
d. Experimental analysis of ligand binding to recombinant E2 by surface 
Plasmon resonance (SPR) detection 
A set of 34 of the ligands predicted by AutoDock to bind to E2 were tested 
experimentally to determine if they bound to recombinant E2 protein immobilized on a 
chip using surface Plasmon resonance detection. The SPR analyses were performed using 
a Biacore T100 workstation (GE Healthcare, NJ, USA) and recombinant HCV E2 protein. 
1 µM HCV E2 was diluted into 10 mM sodium acetate buffer pH 5 and immobilized for 
15 min at a flow speed of 5 µl/min onto a CM5 sensor chip using amine coupling (EDC-
NHS). Approximately 10,000 response units (RU) of protein were immobilized on the 
chip. His-CD81-LEL (Bioclone Inc, San Diego, CA) binding to HCV E2 was tested as a 
positive control prior to injecting the ligands to confirm the E2 protein was functional and 
would bind CD81-LEL. In a typical experiment with CD81, 1µl of his-CD81 (50nM) in 
114 µl PBS was injected into channel 2 and 106.4 RUs of CD81 bound to the E2 on the 
chip. This was followed by testing the binding of the 34 virtual screening hits where the 
ligands were prepared as 200 µM solutions in PBS and they were introduced to the protein 
using a pre-programmed 3 min association and 1 min dissociation interval. The response 
was measured at two time points during dissociation, 10 and 50 seconds, to obtain 
information on the rate of ligand dissociation from E2. 
e. HCV infection assays 
Pseudotyped retroviral particles harboring HCV envelope proteins (HCVpp) from 
different genotypes were produced as described previously [52, 53] with plasmids kindly 
provided by F.L. Cosset, J. Ball, and R. Bartenschlager. A plasmid encoding the feline 
endogenous virus RD114 glycoprotein [54] was used for the production of RD114pp. 
Both HCVpp and RD114pp expressed Firefly luciferase. 
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The cell culture-produced HCV particles (HCVcc) used in this study were based 
on the JFH1 strain [55] and were prepared as described previously [56, 57]. They were 
engineered to express the A4 epitope, titer-enhancing mutations and Gaussia luciferase 
[56,57].  
To identify ligands that inhibit HCV infection, Huh-7 cells were seeded in 96-well 
plates and treated the day after with six different concentrations of each ligand diluted in 
DMSO in duplicate using a Zephyr automated liquid handling workstation (Caliper 
BioSciences, Hopkinton, MA). The final concentration of DMSO (1%) was adjusted to 
be the same for all ligand concentrations. Cells treated with DMSO were used as negative 
controls. Cells treated with different concentrations of anti-CD81 (JS-81 from BD 
Pharmingen, San Jose, CA) 1 hour before infection, were also used as positive controls. 
The third day, RD114pp, HCVpp or HCVcc were inoculated and incubated for 30 hours 
at 37°C. Firefly and Gaussia luciferase assays were performed as indicated by the 
manufacturer (Promega, San Luis Obispo, CA).  
The analysis of the effect of 281816 ligand on Huh-7 infection by HCVpp bearing 
envelope proteins from different genotypes was performed in 24-well plates using the 
method described above. This ligand was also screened for toxicity to the cells using the 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2Htetrazolium) assay [58].  
f. Inhibition of Recombinant E2 binding to native CD81 
The human B cell line Raji (ATCC, Manassas, VA), which expresses high levels 
of CD81 on its surface, was used to determine if ligands inhibit the binding of HCV-E2 
protein to native CD81. Purified HCV-E2 protein (4 µg) was pre-incubated with 1,5,15, 
50, 100 or 400 µM of the ligand 281816 for 25 min at RT. After pre-incubation the E2-
ligand complex was added to the cells and incubated for 25 min. The complexes were 
washed from the cells and 0.5 µg of anti E2 antibody (clone H53) was added followed by 
secondary anti mouse-FITC (Southern Biotechnology, Birmingham, AL). The cells were 
washed, fixed with 3% paraformaldehyde, and analyzed by flow cytometry (BD FACS 
121 
 
Calibur, software: Cell Quest Pro) analysis. The mean fluorescence intensity (MFI) was 
calculated using Flowjo software (TreesStar, www.flowjo.com). 
g. Antibodies  
Mouse anti-E1 A4 [59] and rat anti-E2 3/11 [60] were produced in vitro using a 
MiniPerm apparatus (Heraeus Instruments - Germany). Alexa555-conjugated goat anti-
mouse immunoglobulins were obtained from Jackson Immunoresearch (West Grove, PA). 
JS-81 (PharMingen, Oxford, England) was used according to the manufacturers’ 
protocols.  
h. HCVcc cell-to-cell transmission assay  
Huh-7 cells were seeded on coverslips and infected with HCVcc for 2h at 37°C. 
Cells were then washed and cultured for 72h at 37°C in culture medium containing 
neutralizing anti-E2 antibody (3/11 mAb ; 50ug/ml) in presence of 281816 at the  
indicated concentrations. Cells cultured in presence of DMSO and Epigallocatechin-3-
gallate (EGCG, 50 µM) [35] were used as negative and positive controls of inhibition, 
respectively. Cells were fixed with formalin solution (formaldehyde 4%, Sigma, St Louis, 
MO), and foci detected by indirect immunofluorescence using the anti-E1 monoclonal 
antibody A4. 
i. Kinetics of entry  
Cells treated with 281816 at 10µM or with DMSO were infected with HCVcc for 
1h at 4°C (attachment/binding period). Virus was removed, cells were washed with 
medium and incubated again for 1h at 4°C (post-attachment/binding period). Cells were 
then washed and incubated for 1h at 37°C (endocytosis/fusion period). Lastly, cells were 
washed and incubated in complete culture medium for 21h. Infection levels were 
monitored by measuring luciferase activities. 
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6. Tables 
 
Table 1. Ligands predicted to bind to the HCV E2 protein by blind docking of the NCI 
Diversity set III small molecule library to the HCV E2 structural model. 
 
 
 
 
 
  
Ligand 
ID 
Free 
Energy of 
Binding 
(Kcal/mol) 
 Ligand 
ID 
Free 
Energy of 
Binding 
(Kcal/mol) 
670283 -7.69  211490 -8.7 
86467 -7.47 113486 -6.26 
639174 -7.81 144694 -7.27 
81462 -6.81 4429 -7.3 
403379 -7.58 133071 -7.5 
213700 -7.89 163910 -7.4 
359472 -7.91 54709 -7.3 
146554 -7.67 135618 -8.7 
204232 -8.54 281254 -6.5 
281816 -8.64 319990 -7.4 
308835 -8.4 369070 -6.3 
60785 -7.48 59620 -7.3 
84100 -6.99 38968 -3.9 
158413 -7.9 171303 -5.8 
57103 -6.36 228155 -8.7 
121861 -8.16 13316 -6.8 
3076 -7.71 117268 -7.6 
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Table 2. Magnitude of surface Plasmon resonance binding response obtained for the 23 
ligands that were identified to bind to recombinant E2 protein immobilized on a CM5 
sensor chip. The rate of ligand dissociation is assessed by measuring the response units at 
two time points (10 sec and 50 sec) after the chip with bound ligand is rinsed with buffer.  
 
Ligand 
ID 
Binding 
(RU) 
Dissociatio
n 1 (RU) 
Dissociatio
n 2 (RU) 
670283 54.3 4 1.4 
86467 54.9 1.9 0.8 
639174 55.4 2.3 0.6 
81462 57.2 9.2 6.5 
403379 58 2.8 1.1 
213700 62 3.1 0.8 
359472 62 2.5 0.8 
146554 63.4 3.1 0.8 
204232 63.4 2.5 0.4 
281816 64.5 3.7 0.9 
308835 64.8 7.1 5.2 
60785 70.4 2.8 0.6 
84100 71.2 4.2 2.2 
158413 71.2 10.3 8.5 
57103 81.6 11.4 2.5 
121861 88.4 26.1 20.4 
117268 88.5 4.1 1.2 
3076 92.2 3.2 1.6 
211490 102.9 6.1 2.1 
113486 104.7 7 2.6 
144694 118.8 6 2.3 
4429 155.3 28.9 14.2 
133071 276.3 1.8 -2 
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Table 3. The IC50 values obtained for the 23 ligands screened for their ability to inhibit 
HCVcc, HCVpp and RD114pp infection of Huh-7 cells. ND refers to molecules for which 
the half maximal inhibitory concentration (IC50) against RD114pp was higher than 10 
µM or the molecules that significantly increased RD114pp infection. 
 
Ligand 
ID 
IC50 (µM) 
RD114
pp 
HCVpp HCVcc 
670283 3 ND ND 
86467 >10 >10 >10 
639174 0.03 ND ND 
81462 >10 >10 >10 
403379 >10 >10 >10 
213700 >10 >10 >10 
359472 >10 >10 >10 
146554 >10 ND ND 
204232 >10 >10 >10 
281816 >10 1.02 3.95 
308835 >10 >10 >10 
60785 3.5 ND ND 
84100 >10 >10 >10 
158413 >10 >10 >10 
57103 0.3 ND ND 
121861 >10 >10 >10 
117268 0.1 >10 >10 
3076 0.25 ND ND 
211490 0.5 ND ND 
113486 >10 >10 >10 
144694 >10 >10 >10 
4429 >10 >10 >10 
133071 0.10 ND ND 
Anti-
CD81 
>10 0.17 0.36 
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Table 4. Genotype independent inhibition of HCVpp infection of Huh-7 cells by ligand 
281816. 
 
Subtypes IC50 (µM) 
HCVpp 1a 2.95 
HCVpp 1b 4.66 
HCVpp 2a 2.22 
HCVpp 2b 2.93 
HCVpp 4a 3.44 
HCVpp 6a 3.30 
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Figures  
Figure 1. Comparison of structural templates used for modeling of HCV E2c protein. 
(A) Bar representation of structural similarities between crystal structures 4MWF chains 
C and D, and 4NX3 chain D. Regions reported in coordinates span amino acid residues 
from H421 to N645. In the column Seq_ID are provided sequence identities between 
amino acid sequences taken from coordinates and corresponding sequence fragments 
from HCV E2 protein of genotype 1a. In GREEN are colored regions where structural 
deviations are below 3 Ångstroms measured as Cα-Cα distances between corresponding 
residues from the superimposed structures. In RED are regions where structural data is 
missing or deviations are greater than 3 Ångstroms. (B) Structural superposition of 
4mwf_C and 4nx3_D shows strong conformational similarities between experimentally 
solved structures of E2 proteins for which the level of sequence identity is 69%. In blue 
and purple are colored structural fragments where two structures 4mwf_C (566-601; 
BLUE: light-dark) and 4nx3_D (568-605; PURPLE: light-dark) significantly differ.  
 
(A) 
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(B)  
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Figure 2. Comparison of the crystal structure of E2c with the homology model. 
Structural superposition between E2c crystal structure from the PDB chain 4mwf_D (red) 
and the homology model (black) is illustrated using ribbons representation. It shows 
overlap in structure conformations in most of the regions, except the fragments where 
coordinates in the experimental structure are missing (red dashed lines).  
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Figure 3. . Location of five ligand binding sites used to select ligands for experimental 
testing. Each of these sites either covers or is located immediately adjacent to amino acids 
or peptide segments of the E2 protein known to be important for HCV infectivity. H421-
N423 (yellow): each amino acid in this region important for infectivity. Amino acids 
Y474-R492 (light cyan) have been shown to prevent infectivity, but this region of the 
protein has no effect on E2 binding CD81. W487 (dark cyan) is a key amino acid that is 
involved in E2 binding to E1. S522-G551 (light green) and Y527 and W529 (dark green) 
are critical for E2 binding to CD81. Site 4: P612, Y613, and H617-P619 (red) are critical 
for E2 binding to CD81; mutations to R614-W616 (pink) disrupts the structure of the 
region. 
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Figure 4. Comparison of the crystal structure of E2c with the homology model. A. 
E2c crystal structure (red). B. Homology model (black). C. Superposition of the two 
structures. The residues colored red remain unchanged from the crystal structure. The 
residues colored black show the structure is either different or not present in the crystal 
structure. 
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Figure 5. Surface Plasmon resonance sensogram (Biacore T100).  This figure shows 
sensorgrams (binding and dissociation plots) for two of the ligands that bound to the 
recombinant E2 protein immobilized on a CM5 chip, 86467 (green) and 121861 (red), 
and the 3 reference points that are used to measure the binding and dissociation 
(dissociation 1 and dissociation 2) of the compound expressed in response units (RU). 
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Figure 6. 281816 inhibits HCV entry in a genotype-independent manner. (A) Huh-7 
cells in 96-well plates were pre-treated with 281816 (left and middle panels) or anti-CD81 
antibody (right panel) at the indicated concentrations and then infected with HCVpp 2a 
or HCVcc. (B) Huh-7 cells in 24-well plates were pre-treated with 281816 at the indicated 
concentrations and infected with HCVpp expressing envelope proteins from the indicated 
genotype. After 30 hours of infection, cells were lysed and luciferase activity quantified. 
HCVpp infections were normalized to RD114pp infections. 
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Figure 7. 281816 inhibition of HCV E2 protein binding to CD81 on Raji cells. Flow 
cytometry was used to quantify recombinant HCV E2 protein binding to native CD81 
over-expressed on Raji cells. Binding of the recombinant E2 protein to native CD81 on 
the surface of Raji cells was detected using the mouse monoclonal E2 antibody clone H53 
followed by staining with a secondary anti mouse-FITC antibody as described in the 
Materials and Methods section. E2 binding is inhibited by 281816 in a dose-dependent 
manner up to 100µM.  
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Figure 8. 281816 inhibits HCV entry. A, Huh-7 cells in 24-well plates were treated at 
different time points with 281816 at 10µM and infected with HCVcc for 2h at 37°C. 
281816 was added full-time during the experiment (a), 2h before virus inoculation (b), 2h 
during virus inoculation (c), or full-time after virus inoculation (d). B, Huh-7 cells were 
infected with HCVcc for 1h at 4°C (Step 1: attachment/binding), then virus was removed 
and cells incubated again at 4°C for 1h (Step 2: post-attachment/binding). Finally, cells 
were shifted at 37°C for 1h (Step 3: endocytosis/fusion) and left at 37°C for 21h. 281816 
was added at 10µM either during the Step 1, Step 2, Step 3 or Steps 1-2-3. * and *** mean 
p values below 0.05 and 0.0001, respectively. 
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Figure 9. 281816 blocks HCV cell-to-cell transmission. Huh-7 cells were seeded on 
coverslips and infected with HCVcc for 2h at 37°C. Cells were then washed and cultured 
for 72h at 
presence or in absence of 281816 at indicated concentrations. Cells cultured in presence 
was determined by A4 indirect immunofluorescence. ** and *** mean p values below 
0.001 and 0.0001. 
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Figure 10. 281816 binding sites on HCV E2. 281816 (structure, top) is predicted to bind 
to two sites on the E2 protein. Different conformers of 281816 are shown bound in the 
two sites. The E2 amino acids are color coded as described in Figure 2. 
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CHAPTER VI 
 IN SILICO DESIGN OF SHAL PROTOTYPE (SH2216) AGAINST HCV USING 
HCV E2 AS A TARGET PROTEIN 
Objective 
Designing a bidentate SHAL prototype by selecting 2 potential ligands to be incorporated 
into the SHAL and measuring the distance between their free carboxyl and aminogroups.  
 
1. Introduction 
HCV E2 is considered one of the significant viral proteins that are involved in the 
internalization of HCV into hepatocytes through its interactions with several host proteins 
(1-4). The newly resolved crystal structure of the core of HCV E2 made it easier to 
develop a homology model for the whole or most of the E2 protein (figure 1) (5,6). This 
in turn helps in targeting the model by doing virtual screening runs, analyzing the results 
and determining top virtual screening hits. Upon validating true binders using surface 
Plasmon resonance, those are further tested using infection inhibition assays so as to see 
which has an inhibitory effect on HCV.  
The previous chapter discussed how 281816 was identified to be a genotype-
independent inhibitor in a dose dependent manner. It was also found that 281816 binds to 
several potential binding sites on the E2 model in silico. These results have suggested we 
try to design an in silico bidentate SHAL (SH2216) which is formed of a pair of 281816 
ligand analogue.   
 
 
144 
 
2. Materials and methods 
2.1. Creation of the homology model of E2 used for docking  
Two crystal structures of E2c have recently been deposited in the PDB under codes 
4MWF and 4NX3 were resolved by Kong et al. (5) at a resolution of 2.65 Angstroms and 
Khan et al. (6) at a resolution of 2.4Å. However, upon examination of the structure prior 
to docking, both sets of reported atom coordinates of the protein were found to be 
incomplete. In addition to the coordinate file containing structural information for only 
171 residues out of the 363 amino acids present in the full-length protein structure 
obtained by Kong et al. (5), structural information was missing for several peptide 
segments or loops within the structure. Several peptide segments were also missing from 
the Khan et al. (6) structure file. In order to prepare a more complete version of the 
structure for docking, we have performed several homology modeling and structure 
analysis tasks using the coordinates of Kong et al.’s (5) E2c as a template. The final 
structural model was created using the AS2TS system (7) based on atom coordinates from 
the PDB chains 4mwf_C and 4mwf_D. A structural search for similar fragments in 
proteins in the PDB that could be used to model missing loop regions was performed using 
the StralSV algorithm (8), which identifies protein structures that exhibit structural 
similarities despite low primary amino acid sequence similarity. The side-chain prediction 
was accomplished using SCWRL (9) when residue-residue correspondences did not 
match.  Residues that were identical in the template and E2 protein were copied from the 
template onto the model. Potential steric clashes were identified in the unrefined model 
using a contact-dot algorithm in the MolProbity software package (10), and the 
constructed model was finished with relaxation using UCSF Chimera (11). 
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2.2. 281816 Docking to HCV E2 homology model 
AutoDock 4.2 (12,13) was used to perform 281816 docking to HCV E2 model. 
The parameters were set at 100 for the number of genetic algorithm (GA) runs, 150 as the 
population size, and a maximum number of generations of 25000. The Lamarckian genetic 
algorithm in AutoDock was used to perform the docking experiment. Docking results 
were sorted to identify the binding sites that 281816 binds to and the different between 
free binding energies.  
2.3. Determining an analogue for 281816 and docking it to HCV E2 homology 
model 
One of 281816 Analogues (Ligand 22594527) was chosen to design an in silico 
prototype of SHAL. It was docked to the HCV E2 homology model, and the binding mode 
was analyzed. The binding sites were determined and 2 were chosen. The distance 
between the 2 sites were measured and the number of mini-PEG moieties to be used was 
determined. Avogadro was used to link the 2 281816 ligands with mini-PEG and Lysine 
to create a bi-dentate SHAL (SH2216). 
3. Results and Discussion 
Ligand 281816 was predicted to bind to two different sites on E2 shown in Figure 
2. One site is located deep inside a cavity positioned directly above Y618 and P619, two 
amino acids known to contribute to E2’s binding to CD81. The second site was located in 
a cavity on the opposite of the protein. In this second site, the ligand is positioned directly 
above residues R614-W616 and immediately adjacent to P612 and Y613 and H421-N423. 
These amino acid residues comprise Sites 1 and 4 and the residues in both sites are amino 
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acids that have been shown to be critical for E2 binding to CD81. As expected, the ligand 
positioned above Y618 and P619 in the deeper cavity was predicted to bind more strongly 
to the protein (free energy of the best bound ligand = -8,64 Kcal/mol) than when it was 
bound to the more shallow cavity on the other side of the protein (free energy = -6.39 
Kcal/mol). One interesting and unique feature of the 281816 ligand is that it is predicted 
to bind to both of the exposed faces of the 612-619 domain that is known to participate in 
E2 binding to CD81. 
Owing to the fact that 281816 doesn’t have neither a free amino group nor a free 
carboxyl group, a search for an analogue that has either of these groups was necessary. 
Ligand 22594527 was one of the analogues that were found to be suitable for a SHAL 
synthesis (figure 3). This ligand was docked to HCV E2 model and was found to bind in 
the first site to PRO619 and TRP616 (figure 4a), and in the second site to PRO612 and 
TYR613 (figure 4b) which makes it having similar binding mode to 281816. These 2 
binding sites were chosen depending on the binding modes of Ligand 22594527 and the 
significant residues that were previously determined to be involved in HCV E2: CD81-
LEL interaction. This was followed by measuring the distance between the 2 sites (figure 
4c) which was found to be in the range between 26-27.5 A and determining the number 
of mini-PEG and lysine residues that are needed to link the two molecules together in such 
a manner that one ligand can bind to each site simultaneously.  
 
 
147 
 
4. References  
1. El-Awady, M.K., Tabll, A.A., El-Abd, Y.S., Yousif, H., Hegab, M., Reda, M., El 
Shenawy, R., Moustafa, R.I., Degheidy, N. & El Din, N.G. 2009, "Conserved 
peptides within the E2 region of Hepatitis C virus induce humoral and cellular 
responses in goats", Virology journal, vol. 6, pp. 66-422X-6-66.  
2. Carlsen, T.H., Scheel, T.K., Ramirez, S., Foung, S.K. & Bukh, J. 2013, 
"Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope 
proteins and identification of single amino acids in the E2 stem region important 
for entry", Journal of virology, vol. 87, no. 3, pp. 1385-1399.  
3.  Li, Y.P., Kang, H.N., Babiuk, L.A. & Liu, Q. 2006, "Elicitation of strong immune 
responses by a DNA vaccine expressing a secreted form of hepatitis C virus 
envelope protein E2 in murine and porcine animal models", World journal of 
gastroenterology : WJG, vol. 12, no. 44, pp. 7126-7135. 
4.  Ray, R., Meyer, K., Banerjee, A., Basu, A., Coates, S., Abrignani, S., Houghton, 
M., Frey, S.E. & Belshe, R.B. 2010, "Characterization of antibodies induced by 
vaccination with hepatitis C virus envelope glycoproteins", The Journal of 
infectious diseases, vol. 202, no. 6, pp. 862-866. 
5. Kong, L., Giang, E., Nieusma, T., Kadam, R.U., Cogburn, K.E., Hua, Y., Dai, X., 
Stanfield, R.L., Burton, D.R., Ward, A.B., Wilson, I.A. & Law, M. 2013, 
"Hepatitis C virus E2 envelope glycoprotein core structure", Science (New York, 
N.Y.), vol. 342, no. 6162, pp. 1090-1094.  
6. Kong, L., Giang, E., Nieusma, T., Robbins, J.B., Deller, M.C., Stanfield, R.L., 
Wilson, I.A. & Law, M. 2012, "Structure of hepatitis C virus envelope 
glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33", 
Journal of virology, vol. 86, no. 23, pp. 13085-13088.  
7. Yagnik, A. T., Lahm, A., Meola, A., Roccasecca, R. M., Ercole, B. B., Nicosia, 
A. and Tramontano, A. (2000).A model for the hepatitis C virus envelope 
glycoprotein E2. Proteins. 40, 355-366. 
8. Zemla A, Zhou CE, Slezak T, Kuczmarski T, Rama D, Torres C, Sawicka D, 
Barsky D: AS2TS system for protein structure modeling and analysis. Nucleic 
Acids Res 2005, 33:W111-115. 
9. Zemla AT, Lang DM, Kostova T, Andino R, Ecale Zhou CL: StralSV: assessment 
of sequence variability within similar 3D structures and application to polio RNA-
dependent RNA polymerase. BMC Bioinformatics 2011, 12:226. 
10. Krivov, G.G., Shapovalov, M.V., and Dunbrack, Jr, R.L.: Improved prediction of 
protein side-chain conformations with scwrl4. Proteins 77, 4 (Dec 2009), 778-95. 
11. Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, 
Murray LW, Richardson JS, Richardson DC: MolProbity: all-atom structure 
validation for macromolecular crystallography. Acta Crystallogr D Biol 
Crystallogr 2010, 66:12-21. 
12. Morris, G. M., Huey, R. and Olson, A. J. (2008).Using AutoDock for ligand-
receptor docking. Curr. Protoc. Bioinformatics. Chapter 8, Unit 8.14. 
148 
 
13. Morris, G. M. , Goodsell, D. S., Halliday, R. S.,  Huey, R.,  Hart, W. E. , Belew, 
R. K., Olson, A. J. (1998). Automated docking using a Lamarckian genetic 
algorithm and an empirical binding free energy function, J. Comput. Chem. 19, 
1639–1662. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
149 
 
5. Figures 
Figure 1. The four binding sites selected to guide the virtual screening runs on HCV 
E2 homology model. Site 1: Yellow (412-423) each amino acid in this region important 
for infectivity. Site 2 Light cyan (474-492) prevents infectivity, no effect on E2 binding 
CD81; Dark cyan 487 (involved in E2 binding to E1). Site 3 Light green (522-551); Dark 
green 527, 529 (critical for E2 binding to CD81). Site 4: Red (612, 613, 617-619, critical 
for E2 binding to CD81); Pink (614-616) disrupts structure of region. 
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Figure 2. 281816 binding sites on HCV E2. 281816 binds three sites. Clusters of 
different conformations of bound 281816 molecules are shown bound in the three sites. 
Sites and amino acids are color coded as described in Figure 2. 
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Figure 3. The structure of 281816 analogue. 281816 analogue (22594527)- Z)-but-2-
enedioic acid;N'-(3-methylsulfanyl-5,6-dihydrobenzo(b)(1)benzothiepin-5-yl)ethane-
1,2-diamine. 
CSC1=CC2=C(C=C1)SC3=CC=CC=C3CC2NCCN.C(=CC(=O)O)C(=O)O 
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Figure 4. The 2 chosen binding sites that ligand 22594527 binds to. The first site 
comprises residues PRO619 and TRP616 (a) and the second site compromises PRO612 
and TYR613 (b). The distance between the free aminogroup of the first ligand binding to 
site (a) and that binding to site (b) was found to be in the range 26-27.5 A (c).  
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Figure 5. Bidentate SHAL from 2 ligands 22594527. The distance between the 2 ligands 
binding on the same site is around 10.22 A. Which enables generating a bidentate (b) and 
tridentate (c) SHAL without the use of linkers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C(CC(=O)NCCNC2C3=C(SC1=CC=CC=C1C2)C=CC(=C3)SC)(C@@H)(C(=O)NCCNC
5CC4=CC=CC=C4SC6=C5C=C(C=C6)SC)NC(C(CCCCN)N)=O 
A 
B 
C 
C(CC(=O)NC(C(=O)NCCNC2CC1=CC=CC=C1SC3=C2C=C(C=C3)SC)CCC(=O)NCCNC5CC4=CC=CC=
C4SC6=C5C=C(C=C6)SC)(C@@H)(C(=O)NCCNC8CC7=CC=CC=C7SC9=C8C=C(C=C9)SC)NC(C(CC
CCN)N)=O 
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CHAPTER VII 
 IDENTIFICATION OF DRUG LEADS THAT BLOCK PLASMODIUM 
SPOROZOITES: CD81-LARGE EXTRACELLULAR LOOP INTERACTION 
Objectives 
The aim of this study is to screen ~2000 ligands against the residues in CD81-LEL 
that are involved in CD81: Plasmodium sporozoites interaction, test the hits using lab on 
a chip techniques and antibody neutralizing assays followed by testing the ligands with 
the best binding affinity using Sporozoite Invasion assays. The Sporozoite invasion assays 
were conducted in John Hopkins University (USA) at Dr. Photini Sinnis’s lab.  
 
1. Introduction 
Malaria is caused by protozoan parasites belonging to the genus Plasmodium. 
Malaria in human is caused by four types which are: Plasmodium malariae, Plasmodium 
ovale, Plasmodium vivax and Plasmodium falciparum. P. falciparum and P. vivax are the 
two major species involved in global malaria (1). Malaria infection starts by the invasion 
of the parasite into the hepatocytes (Liver stage) followed by blood stage.   
In order for Plasmodium species to propagate in the host and establish an infection, 
they should be internalized into the hepatocytes (2). The mechanism of interaction of 
plasmodium sporozoites with hepatocytes is still not clear however, hCD81 was found to 
be one of the significant surface proteins on the hepatocytes required by the sporozoites 
to invade the liver cells (3-5).  
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CD81 belongs to tetraspanin family. It possesses ubiquitous functions such as cell 
adhesion, migration, cell fusion, co-stimulation, signal transduction, and differentiation 
(Reviewed in 6). It was found that antibodies to CD81 or CD81 silencing largely inhibits 
the infection of hepatocytes by Plasmodium falciparum sporozoites. Additionally, it was 
found that Plasmodium yoelii sporozoites do not have the ability to infect CD81-deficient 
mouse hepatocytes both in vitro and in vivo (3-5).  
Yalaoui et al. (7) identified specific amino acid residues in CD81 that are 
important for infection through conducting mutational studies. They found a stretch of 21 
amino acid residues that are required for invasion (135-
VVDDDANNAKAVVKTFHETLD-155) (figure 1) (7).  
In our study we targeted those amino acid residues by creating 3 grid parameter 
files (figure 2), used them to guide the virtual screening runs against ~ 4000 ligands, 
analyzed 500 of the resulting docked ligands, determined the virtual screening hits and 
tested the hits in vitro using surface Plasmon resonance and antibody neutralizing assays 
to validate binding to CD81 and inhibition of CD81: antibody interaction. 
2. Materials and Methods 
2.1. In silico Experiments  
In this study we used three different grid boxes (3 regions) to encapsulate the 
region of CD81 that has the amino acid residues involved in malaria infection of liver 
cells. A total of ~4000 ligands from the NCI Library were docked against each of these 
grid boxes in the crystal structure of hCD81 (PDB ID: 1G8Q). This was followed by 
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analyzing the results (filtering, visually inspecting and determining virtual screening hits. 
Thirty one hits were chosen to be tested in vitro.  
 
2.2. Surface Plasmon Resonance 
SPR analysis was performed using a Biacore T100 workstation (GE Healthcare, 
NJ, USA). A recombinant form of the CD81-LEL protein with a GST-tag (Shoshana Levy 
Lab - Stanford) was used to determine the binding affinities of the 31 ligands. 10 uM 
CD81-LEL-His diluted into 10 mM sodium acetate buffer pH 4.5 was immobilized for 15 
min at a flow speed of 5 ul/min onto a CM5 sensor chip using amine coupling (EDC-
NHS). Approximately 20,000 RU of protein were immobilized on the chip. The ligands 
were prepared as 200 uM solutions in PBS-1% DMSO (the running buffer) and they were 
introduced to the protein using a pre-programmed 3 min association and 1 min 
dissociation interval. 
2.3. Antibody Neutralizing assays 
For antibody neutralization assay Raji cells were used, a human B cell line that 
expressed high amounts of CD81 on the surface (data not shown). Cells were grown in 
RPMI medium (10% FCS, 1% penicillin/streptomycin, 1% L-glutamine, 1% non-
essential amino acids, 1% sodium pyruvate, pH 7.4, at 37oC with 5% CO2). 2x105 cells 
were incubated with or without different concentrations (50 µM, 100 µM, 400 µM and 1 
mM) of indicated inhibitor for 20 min at room temperature, subsequently 1 ul (16 ng/µl) 
of FITC-labeled anti CD81 antibody (BD Pharmingen, 551108) was added to the cells 
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and incubated for 20 min (antibody titration was performed to obtain a working dilution 
range, data not shown). Cells were washed and analyzed by FACS (BD FACSCalibur, 
software: Cell Quest Pro). Mean Fluorescence Intensity MFI was calculated using Flowjo 
software (TreesStar, www.flowjo.com). 
2.4. Mosquito Infection  
Anopheles stephensi mosquitoes were fed on mice infected with Plasmodium 
yoelii 17XNL parasites. On day 14 post bloodmeal, salivary glands were harvested, 
homogenized, sporozoite number was determined using a hemocytometer and the 
indicated number of sporozoites was added to cell monolayers. Plasmodium falciparum 
sporozoites were generated by membrane feeding An. stephensi mosquitoes using 
gametocyte cultures generated in vitro.  
2.5. Cells and antibodies.  
HepG2-CD81 cells (8), which are derived from human liver carcinoma and express 
CD81, were maintained in DMEM supplemented with 10% fetal calf serum and 1 mM 
glutamine (DMEM/FCS). Monoclonal antibody (mAb) 2E6 was used for development 
assays and is directed against Plasmodium Hsp 70 (9) and mAb 2A10 is directed against 
the repeat region of P. falciparum CSP and was used for invasion assays.  
2.6. Invasion and development assays.  
5 x 105 HepG2-CD81 cells were plated on collagen coated Lab-Tek wells and allowed 
to adhere overnight. The following day, cells were preincubated with 400 uM of 
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compound for 30 minutes at 37oC. Controls were pre-incubated with DMSO at the same 
concentration in which it was found in the compound solutions. 105 sporozoites were 
added to each well and in the case of P. falciparum, incubated for 1.5 hours and scored 
for invasion whereas in the case of P. yoelii, incubated for 44 hours and scored for 
exoerythrocytic stages.  
3. Results 
Eight out of 31 ligands were found to bind to CD81 using surface Plasmon 
resonance based assays (Table 1 – Figure 3). Ligand 87504 was found to be the one with 
the most desirable binding-dissociation behavior having the highest binding RUs. Ligand 
90444 and 93033 are considered of comparable binding and dissociation.  
In addition, the eight ligands had inhibitory effect on CD81: antibody interaction 
(Table 2). As shown, they were found to have a better inhibitory effect at concentration 
of 400uM when compared to that of 100uM.  
When sporozite infection assays were conducted with the ligands, four ligands 
were found to inhibit P. yoleii (7962, 73735, 90444 and 75866) whereas ligand 40614 
exhibited an interesting action where it enhanced the infection with P. yoelii (figure 4). 
Inhibition of P. berghei by both ligands 7962 and 73735 was detected when using Hep1-
6 hepatoma cells whereas 90444 and 75866 didn’t inhibit P. yoleii or P. berghei in Hepa1-
6 cells. Ligand 40614 was found to be consistent in enhancing development in both P. 
yoleii and P. berghei in both Hepa1-6 and Hep2G cells (figure 5). As for the infection by 
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P. falciparum, 7962 and 73735 were found to inhibit the infection with this species. On 
the other hand, 40614 wasn’t found to enhance infection with Pl. falciparum (figure 6). 
During our in silico analysis of the binding modes of 7962 (the most promising 
drug lead among the five tested compounds), we found that there are a number of 7962 
conformations that interacted with the 21 amino acid sequence and Asp137 that were 
known to be important for malaria infection (figure 7). As for 73735, some conformations 
interacted with the peptide sequence and others bound near Asp137 (figure 8). The 
majority of 40614 ligand conformers did not interact with the peptide sequence nor near 
Asp 137. Only two 90444 ligand conformers were found to bind (weakly) nearby the 
peptide but not close to Asp137. As for 75866, only few 75866 ligand conformers were 
found to bind nearby the peptide sequence but none were found to bind near to Asp137.  
Upon calculating the percentage of infection inhibition of the 3 Pl. species by the 
five ligands, 7962 was found to exhibit a 100% inhibition of all 3 species whereas 73735 
was found to possess an inhibitory percentage of 96.8%, 77%, and 82.3% of infection 
with P. falciparum, P. yoleii and P. bergeii respectively.  
4. Discussion 
Upon conducting virtual screening runs, 31 ligands were selected to be the first set 
for conducting experimental validation using surface Plasmon resonance. Eight of the 
virtual screening hits were found to bind to CD81 using surface Plasmon resonance. 
Ligand 87504 was one of the ligands that showed best binding and dissociation thus when 
going back and analyzing it’s in silico binding behavior it was found to bind to several 
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residues in the stretch of 21 amino acid residues identified by Yalouli et al. (7) to be 
involved in Plasmodium : CD81-LEL interaction (figure 1).  
Those eight ligands were further tested using antibody neutralizing assays and 
were found to inhibit anti-CD81 binding to CD81-LEL in a dose dependent manner where 
the 400uM concentration gave better inhibitory effect compared to the 100uM of the 
ligands ranging from % of inhibition of 17% to ~30%.  
There are three features of 7962 and 73735 (ligands that block sporozite infection) 
that docking experiments suggest may distinguish them from 40614, 90444 and 75866 
(ligands that do not block infection): (i) 7962 and 73735 conformers, in general, bind more 
strongly to CD81 (1-3kcal/mole). (ii) The strongest binding conformers of 7962 and 
73735 were found to bind to the red site A (figure 7, Figure 8). (iii) The higher number of 
7962 and 73735 conformers are predicted to bind to or nearby Asp137; where none of the 
40614, 90444 or 75866 conformers were predicted to bind near or to Asp137 which was 
shown to be essential for infection. Collectively, these data suggest that ligand 7962 would 
help generate a promising drug to treat several species of malaria. 
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6. Figures 
Figure 1. Stretch of 21 amino acid residues involved in plasmodium sporotzoites: 
CD81-LEL interaction. Red, Green, Blue: amino acids surrounding three main ligand 
binding sites. Light orange: V135-D155 - Dark orange: D137 (7). 
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Figure 2. The 3 sites chosen on CD81-LEL to undergo virtual screening runs. Those 
sites were based on the stretch of 21 amino acids where the site containing those residues 
was fragmented into 3 subsites and each of them included other residues.  
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Figure 3. Bar chart representing the change in response units of the ligands that were 
found to bind to CD81-LEL using surface Plasmon resonance. The chart shows that 
87504 had the best binding – dissociation behavior with CD81-LEL whereas 90444 had 
the least desirable binding-dissociation behavior.  
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Figure 4. Binding of ligand 87504 to site 1 
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Figure 4. Inhibition of P. yoelli Infection of HepG2 Cells. Ligand 7962 was found to 
have the strongest inhibitory effect followed by ligand 73735, 75866 and 90444. Ligand 
40614 was found to enhance the infection with Pl. Yoleii in HepG2-CD81(a). The gliding 
Assay(b). 
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Figure 5. Inhibition of P. yoelli & P. berghei Infection of Hepa1-6 Cells. Ligands were 
tested using Hepa 1-6 cells which express less CD81 so as to see the difference in behavior 
compared to HepG2 cells that express higher no. of CD81…It was found that both 
Ligands 7962 and 73735 exhibited an inhibitory effect yet, ligands 90444 and 75866 
didn’t show any inhibitory effect in case of Plamodium yoleii (a) and Plasmodium berghei 
(b).  
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Figure 6. Comparison of Inhibition of P.y. and P.f. Infection of HepG2 Cells. The 
results of ligands tested using HepG2 cell line (a) were compared to its effect on infectivity 
of P.y and P.f. It was shown that ligands 7962 and 73735 affect the invasion step and not 
post invasion whereas ligands 90444 and 75866 affects steps other than invasion where 
in case of P.f. invasion is the only step observed (parasites inside ersus outside of the cell). 
40614 does not enhance infection in Pf (may affect post invasion event) (b).  
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Figure 7. The different binding modes of 7962 to CD81. A number of 7962 
conformations interacted with the 21 amino acid sequence and Asp137 that were known 
to be important for malaria infection. 
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Figure 8. The different binding modes of 73735 to CD81. A number of 7962 
conformations interacted with the 21 amino acid sequence and Asp137 that were known 
to be important for malaria infection. 
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7. Tables 
Table 1. Surface Plasmon Resonance Experiment. This table shown the change in 
response units in relation to binding and dissociation of the 8 ligands that were tested. 
 
Ligand ID Binding (RU) Dissociation 1 (RU) 
Dissociation 2 
(RU) 
87504 72 57.9 42.6 
40614 52.5 50.8 43 
7962 43.6 14.7 10.1 
30930 38.6 26.8 21.8 
98026 36.6 35.9 28.1 
75866 14.3 18.9 11.3 
93033 6.7 16.8 7.9 
90444 -1.7 13.1 5.6 
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Table 2. Percentage of infection inhibited by the 5 tested ligands in the 3 Plasmodium 
sp. Two cell lines were used to show the reduction in infectivity of Pl. sporozoites (HepG2 
cells and Hepa 1-6)  
 
Ligand Percent Infection 
HepG2-CD81 Hepa1-6 Cells 
P.f. P.y. P.y. P.b. 
73735 3.2 23 38.3 17.7 
90444 98.7 44.3 222 95.6 
7962 0 0 0 0 
40614 86.2 234 238 167 
75866 84.2 42.6 122 135 
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CHAPTER VIII 
 CONCLUSIONS 
AutoDock and its tool AutoLigand proved to be very helpful in identifying 
potential ligand binding sites on the surface of CD81-LEL. In addition to generating fill 
points for each cavity and using the collective points to provide information about the 
volume and depth of the cavity, a feature common to most docking programs, properties 
were identified for specific point groupings (features equivalent to atoms or functional 
groups) that would optimize the ligand’s interaction with specific atoms lining the inner 
surface of the cavity. Using AutoLigand, we also increased our efficiency of identifying 
new molecules that bound to the protein. Previous studies using earlier versions of 
AutoDock that did not contain AutoLigand yielded results in which 25-55% of predicted 
binders actually bound to the target protein when tested experimentally. The virtual ligand 
screens (docking runs) performed in this study led to the identification of a diverse group 
of new small molecules that bind to CD81-LEL. A set of 36 ligands were tested by SPR 
and DPI to obtain a set of 26 new molecules we can use to develop inhibitors that block 
HCV invasion. Four of these ligands were observed to exhibit stronger or similar binding 
to CD81-LEL as benzyl salicylate, a small molecule reported to be a moderate inhibitor 
blocking the binding of HCV E2 to CD81. One of these ligands, 689002, has been found 
to inhibit the binding of HCV E2 to CD81-LEL. 689002 and the other ligands identified 
in this study will be used to develop second generation leads that bind more tightly to 
CD81-LEL using fragment-based drug design methods, and different combinations of Site 
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1 and Site 2 ligands will be linked together to create selective high affinity ligands called 
SHALs.  
Two ligands, 689002 and 93033 were linked together to form a bidentate SHAL 
(SH7153). Using SPR analysis, SH7153 was found to bind to CD81-LEL when tested 
using SPR. But flow cytometry assays and HCV infection inhibition assays showed that 
SH7153 didn’t have an inhibitory effect. This might be either due to the length of linkers 
which might need optimization or exchanging one of the two ligands with a new ligand 
that shows better binding mode in silico. 
HCV E2 glycoprotein has a major role in the viral entry and its pathogenic effects 
being involved in different interactions with different host factors. Several research groups 
targeted different HCV proteins like serine protease and polymerase. The availability of 
the core structure of HCV E (E2c) (12) makes it feasible to generate a drug that targets 
the early stage of HCV via blocking HCV E2 interaction with different host factors. 
Although E2 has several hypervariable regions where HVR1 is highly mutative, targeting 
conserved residues in HCV E2 might help generate a drug that treats several HCV 
genotypes and subtypes.  
In this study a structural model of the HCV E2 protein has been created using the 
E2c crystal structure as a template. Docking studies conducted with this model have led 
to the identification of 23 small molecule drug candidates that bind to the E2 protein. We 
were able to identify a new drug lead, 281816, which was found to inhibit HCV genotypes 
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and subtypes (1a, 1b, 2a, 2b, 3, 4a and 6a). This new drug lead might offer a new paradigm 
in HCV treatment. It might also be interesting to develop a cocktail of drugs that target 
E2 binding site on CD81 and CD81 binding site on E2, hence completely blocking the 
HCV E2: CD81 interaction and downstream pathogenic effects. 
In several studies, SHAL were shown to increase the binding affinity when 
compared to single ligands. Hence, an in silico bidentate SHAL (SH2216) based on the 
studies on HCV E2 model was designed in silico. 281816 was shown to bind to several 
potential binding sites on the created homology model that comprises several significant 
residues such as PRO619 and TRP613. Owing to the fact that 281816 doesn’t have neither 
free amino group nor free carboxyl group, a search for an analogue that do have one of 
these groups was conducted. Ligand 22594527 was found to have a free amino group. It 
was docked to the model to compare its binding modes to that of 281816 and it was found 
to have the same desirable binding to HCV E2. Two binding sites were chosen and the 
distance between the aminogroup of the first ligand and that of the second between the 2 
sites was measured and an in silico designed SHAL was designed accordingly linking the 
2 ligands with mini-PEG and lysine moieties.  
Knowing that CD81 is a common target for HCV and malaria, we identified the 
significant residues involved in plasmodium sporozoite: CD81 interaction that are 
responsible for sporozoite invasion into the hepatocytes based on previous research done. 
We targeted those residues using AutoDock and did virtual screening runs against a 
library of ~4000 ligands. Eight out of thirty one ligands tested using surface Plasmon 
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resonance were found to bind to CD81. They were further tested using antibody 
neutralizing assays to see which inhibit binding CD81 to JS-81 antibody. They were also 
found to inhibit the JS-81: CD81 binding. Upon testing 5 of them using sporozoite 
invasion assay, Ligands 7962 and 73735 were found to inhibit P. falciparum, P. yoleii and 
P. berghei at 400uM conc.  
Collectively, the approach adopted throughout the PhD project depended on 
determining virtual screening hits based on in silico analysis of the virtual screening 
results, testing them using surface Plasmon resonance to confirm binding to the target 
protein, followed by antibody neutralizing assays to validate that they may have an 
inhibitory effect of the infection and ending with infection inhibition assays and 
sporozoite invasion assays.   
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CHAPTER IX 
FUTURE PERSPECTIVES 
A library of promising compounds resulted from this study and this in turn 
necessitates the continuation of analyzing other subsets of these compounds for binding 
either to CD81 or HCV E2. Additionally, the drug leads that were already identified 
should be further tested in cell culture and animal models to be able to conduct 
pharmacokinetics and pharmacodynamics studies. 
Since generating SHALs is considered a beneficial approach when it comes to 
increasing the binding affinity to the target protein. Selecting different hits against CD81 
and generating a cocktail of bi-dentate and tridentate SHALs from them would help come 
up with a better drug candidate; since as the number of ligands increase in a SHAL, the 
binding affinity increase (Bi-dentate  Tri-dentate). It would also be helpful to try 
different lengths of the linkers in SH7153 so as to see whether the non-inhibitory effect 
was attributed to the linkers’ length being not suitable or to the included ligands 
themselves (689002 and 93033).  
281816, one of the promising drug leads was found to inhibit HCV in a genotype-
independent manner. Testing it using a suitable HCV animal model would help take a step 
further towards confirming if this is a suitable drug candidate for the treatment of HCV. 
Additionally, it might be useful to synthesize SH2216 based on the in silico designed one, 
test it and compare its inhibitory effect to that of 281816 alone. It would also be interesting 
to test other 281816 analogues (figure 1) to observe their inhibitory effect as well.  
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The identified drug leads that are targeting the plasmodium sporozoite: CD81 
interaction should be further tested using sporozoite invasion assay. This will help identify 
the best inhibitors and optimize them further to be suitable drug candidates.  
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Figure 1. 281816 analogues that were found to be FDA approved for treating 
different diseases.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31 
Amitriptyline 
zinc968257 
C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl 
Amoxapine (211µM) 
zinc93
1 
CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl 
Loxapine 
zinc1639 
zinc19632628 
C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42 
Quetiapine 
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Table 1. The 281816 drug analogs and their corresponding indications 
Analog/Drug Indications 
Amoxapine Antidepressant  
Amytryptiline Tricyclic antidepressant 
Loxapine Typical Antipsychotic  
Quetiapine Atypical Antipsychotic  
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CHAPTER X 
NOVELTY 
The novelty of the work done in this thesis project lies in targeting the entry phase 
of HCV instead of the replication and translation process which is targeted by polymerase 
and protease inhibitors. The aim of this project was to identify drug leads that have the 
ability to block the entry phase of HCV via blocking HCV E2: CD81-LEL interaction and 
thus altering any upstream processes. The two main protein targets that were used were 
CD81-LEL and HCV E2. In case of HCV E2, a homology model was created based on 
the newly resolved crystal structure of the core of HCV E2 (E2c) (PDB ID: 4MWF), and 
this was further used in virtual screening to identify potential hits that could block the 
entry phase. This helped identify a promising drug lead (281816) that was found to block 
HCV infection and cell to cell transmission. On the other hand, specific residues in CD81-
LEL that were known to interact with HCV E2 from previously published literature were 
targeted so as to identity additional set of hits that could block the entry phase.  
Beside targeting HCV, CD81-LEL was known to be involved in malaria infection 
through interacting/facilitating the internalization of the Plasmodium sp. Sporozoites 
invasion into the hepatocytes. Accordingly, we targeted the specific residues in CD81-
LEL that were known to be involved in internalization of malaria sporozoites. This in turn 
led to the identification of 2 drug leads that were found to exert inhibitory effects on Pl. 
falciparum which is one of the most aggressive human plasmodium parasites.  
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CHAPTER XI 
 ORIGINALITY STATEMENT 
‘I hereby declare that this submission is my own work and to the best of my 
knowledge it contains no materials previously published or written by another person, or 
substantial proportions of material which have been accepted for the award of any other 
degree or diploma at AUC or any other educational institution, except where due 
acknowledgement is made in the thesis. Any contribution made to the research by others, 
with whom I have worked at AUC or elsewhere, is explicitly acknowledged in the thesis. 
I also declare that the intellectual content of this thesis is the product of my own work, 
except to the extent that assistance from others in the project's design and conception or 
in style, presentation and linguistic expression is acknowledged.’  
  
  
Signed: Reem R. Al Olabi.  
Date: 5/18/2014 
 
